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NPRL2/TUSC4 FUNCTIONS AS A TUMOR SUPPRESSOR BY REGULATING 
BRCA1’S STABILITY VIA THE E3 UBIQUITINATION PATHWAY 
 
Yang Peng, M.S 
Supervisory Professor: Shiaw-Yih Lin, Ph.D 
 
Expression of the tumor suppressor protein BRCA1 is frequently lost in breast 
cancer patients, and the loss of its expression is associated with disruption of 
various critical functions in cells and cancer development. In the present study, 
we demonstrate through  microarray analysis that cells with tumor suppressor 
candidate 4 (NPRL2/TUSC4) knockdown show critical changes to cell cycle, cell 
death pathways and a global impact on cancer development. More importantly, 
we observed a clear cluster pattern of NPRL2/TUSC4-knockdown gene profiles 
with established homologous recombination (HR) repair defect signature. 
Additionally, NPRL2/TUSC4 protein physically interacts with the E3 ligase 
HERC2 and prevents ubiquitin pathway-mediated BRCA1 degradation. 
Knockdown of NPRL2/TUSC4 expression enhanced BRCA1 polyubiquitination, 
leading to BRCA1 protein degradation and a marked reduction in HR repair 
efficiency. Conversely, ectopic expression of NPRL2/TUSC4 effectively 
suppressed the proliferation, invasion, and colony formation of breast cancer 
cells in vitro and tumorigenesis in vivo. Furthermore, knockdown of 
NPRL2/TUSC4 expression transformed normal mammary epithelial cells and 
vi 
 
enhanced the sensitivity of U2OS cells to the treatment of poly(ADP-ribose) 
polymerase inhibitors. Therefore, NPRL2/TUSC4 may act as a bona fide tumor 
suppressor by regulating BRCA1 protein stability and function in breast cancer. 
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Chapter 1 
 
INTRODUCTION AND BACKGROUND 
 
BRCA1 maintains DNA damage response in breast cancer 
 
Tumor suppressor and cancer development 
        According to Hanahan and Weinberg’s updated review in 2011, they re-
defined the six classical hallmarks of cancer development: sustaining proliferative 
signaling, resisting cell death, inducing angiogenesis, enabling replicative 
immortality, activating invasion and metastasis and evading growth suppressors 
(Hanahan and Weinberg, 2011). This concept systematically and fundamentally 
explains the most critical characteristics most cancer cells need to acquire during 
their development.  However, it’s unlikely these abnormities would occur 
synchronically and naturally under normal circumstances, instead it’s more likely 
that the tumor proliferation is regulated sequentially, while any of these defects can 
be raised. For example, sustaining proliferative signaling also requires cancer cells 
disrupt the normal growth regulation mechanism, and lead to the evasion of cell 
growth suppressors, but many of these processes are conducted by tumor 
suppressor genes. Tumor suppressors operate in numerous ways to limit cell 
growth and proliferation to prevent cancer.  Genome-wide screening has shown 
that many tumor suppressor genes are deleted or mutated in various types of 
cancers, with the inactivation patterns of many well-recognized tumor suppressor 
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genes being well characteristic and non-randomized (Vogelstein et al., 2013). 
Recent studies also confirmed the mutation of certain tumor suppressor genes 
confers to selective tumor growth advantages (Xue et,al., 2012). 
 
BRCA1 and breast cancer 
        As the most diagnosed and leading cause of cancer-related deaths in women, 
breast cancer is responsible for the 180,000 new cases in the United States alone 
and 1.6 million worldwide, while more than a half million women died in 2011 
primarily due to the lack of early detection  (Global Health Estimate, WHO 2013). 
Among those cancer patients, women with BRCA1 mutations are six times more 
likely to develop cancer before the age of 70 compared to women with normal 
BRCA1 (NCI, 2014). Thus to investigate the relationship between BRCA1 and 
breast cancer as well as how BRCA1 is regulated before the early cancer lesions 
posed extreme challenges and remarkable clinical potentials to current breast 
cancer research fields.  
 
DNA damage response and BRCA1 
           DNA damage can be caused by various sources, and leads to genomic 
stress for the cell. To safeguard the integrity and fidelity of genomic information, 
cells activate the evolutionary conserved DNA damage response pathways to 
manage the lesions once the lesions are found. Cell cycle checkpoints will stop the 
damaged cells from dividing and activate the damage repair mechanisms. If the 
DNA damage lesion can be fixed, cell cycle will restart, otherwise, the cells will be 
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eliminated by apoptosis pathway (also known as programmed cell death) (Medema 
and Macurek, 2012). Depends on the damage types, different pathways are 
responsible for the DNA double strand breaks (DSB) and DNA single-strand break 
(SSB). Most current understanding indicate that Ataxia Telangiectasia Mutated 
(ATM) and Ataxia Telangiectasia and Rad3-Related (ATR) are the main players in 
mediating cells' DSB and SSB responses respectively, although the molecules 
involved in each pathway can overlap (Ciccia and Elledge, 2010) (Figure 1).  Upon 
the recognition of DNA breaks by sensor proteins, ATM and ATR quickly undergo 
the autophosphorylation or phosphorylation of their substrates, such as CHK1 and 
CHK2 (Zhou and Elledge, 2000). Histone protein H2AX will rapidly get 
phosphorylated at Ser-139 by ATM or ATR and produce γ-H2AX at the damage 
sites, in turn recruit other damage repair proteins to the broken DNA. ATM and 
ATR also phosphorylates their own unique substrates to stimulate DSB and SSB 
responses respectively. More specifically, ATM phosphorylates checkpoint kinase 
2 (CHK2) at Thr-68 and ATR phosphorylates checkpoint kinase 1 (CHK1) at Ser-
317 and Ser-345. CHK2 phosphorylation in turn leads to p53 phosphorylation, 
MDC1, RNF8, RNF168, BRCA1 and 53BP1 recruitment to the damage sites while 
CHK1 phosphorylation is followed by the phosphorylation of Cdc25A and Tlk1/2. 
These processes induce downstream processes that includes damage-induced 
transcription, DNA repair, cell cycle arrest/delay, apoptosis and chromatin 
remodeling (Bartek and Lukas, 2003).         
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BRCA1 safeguards genome integrity and regulates DNA damage repair 
            BRCA1 gene was first identified and cloned in 1994. BRCA1 protein 
contains 1863 amino acids and located on chromosome 17q21. Its C-terminus has 
BRCT motif to recognize and interact with various DNA repair proteins, while its N-
terminus contains a ring-finger domains allowing proteins interactions such as 
BRCA1-associated RING domain-1 protein (BARD1) to form heterodimer, and this 
complex was confirmed to carry ubiquitination ligase activities (Xia et al., 2003). 
BRCA1 plays multiple roles to regulate normal molecular and cellular functions 
such as cell cycle checkpoint control, mRNA transcription regulation and DNA 
damage repair (Kennedy et al, 2004)(Figure 3). Loss-of-function mutation for 
BRCA1 correlates with approximately 82% risk of developing breast cancer (King 
et al., 2002) (Figure 2) and low BRCA1 expression is associated with significant 
increase of sporadic cancer incidences (Couch et al., 1997; Wang et al., 2004).   
        There are two major DNA damage repair mechanisms involve in mammalian 
cells, homologous recombination (HR) repair and non-homologous end joining 
repair. Previous reports indicated that BCRA1 play important roles in both repair 
pathways and it involves intensively in HR repair to protect cells to repair DNA 
double-strand break (DSB) in a least error-prone manner (Figure 4). 
 
Role of BRCA1 in homologous recombination (HR) repair 
           HR repair has been considered as one of the most important mechanism to 
maintain genomic stability during DSB by mediating error-free repair (Levitt and 
Hickson 2002). The deficiency of HR repair is associated with cancer development 
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and sensitize DNA damage-inducing therapy (Alli et al., 2009).  When DNA DSB 
occurs, HR repairs DNA during the S and G2 phases and before M phase of cell 
cycle. After cell sensing the DSB, BRCA1 will be recruited and form protein 
complex with Rad50, MRE11 and NBS1 (also known as MRN complex), the 
BRCA1-MRN complex can take 5’—3’ exonuclease activity and expose 3’ end of 
the break DNA, either single-strand annealing or strand invasion will occur during 
the process of repair (Karran 2000). It is believed that BRCA1 participates in the 
strand invasion repair system and also physically interact with BRCA2, RAD51 to 
form repair complex at the DNA damage break sites (Karran 2000; Gilmore et al., 
2003), based on the earliest evidence from the previous reports that BRCA1 
deficient in stem cells leads in the increased sensitivity to alkylating reagents which 
commonly used to cause DNA DSB (Moynahan et al., 2001). Recent works 
supported this statement that mutation or inactivation of BRCA1 will not only impair 
HR repair efficiency but also decrease the accuracy of NEHJ repair pathway and 
eventually enlarge the effect of DNA damage toxicity and increase the possibility of 
early cancer lesions.  
 
Role of BRCA1 in cell cycle regulation and drug sensitivity 
         BRCA1 has been reported to be a cell cycle regulator majorly owing to its role 
as the substrate of DNA damage kinases such as ATM and ATR, and Checkpoint 
Kinase 2 (CHK2) (Yarden et al., 2002; Xu et al., 2001; Xu et al., 2002). ATM and 
ATR mainly respond to DNA double strand breaks such as ionizing irradiation and 
DNA single strand breaks such as Ultraviolet respectively (Zou and Elledge 2003). 
 
 
- 6 - 
 
BRCA1 can be phosphorylated by ATM, ATR and CHK2 at various sites, and in 
turn activate the checkpoint of cell cycle (Cortez et al., 1999; Lee et al., 2000; 
Tibbetts et al., 2000). It has been suggested that phosphorylated BRCA1 is 
associated with transcriptional activation of multiple critical checkpoint proteins and 
stimulate their expression level such as p21, p27 in G1/S phase arrest by inhibiting 
cyclin-depedent kinase 2(CDK2), but mechanism of how BRCA1 is involved in cell 
cycle checkpoint remains unclear (Somasundaram et al., 1997).  
        Additionally, mouse embryonic fibroblast with mutated BRCA1 showed 
increased DNA damage causing drugs’ sensitivity such as Irinotecan and 
Etoposide which target DNA topoisomerase I and II respectively (Fedlier et al., 
2003). Accumulating evidence indicated BRCA1 is important in the inhibition of cell 
apoptosis after the treatment of DNA-damaging drugs, especially in breast cancer 
cell lines (Kennedy et al., 2004). Thus, the disruption of BRCA1 will significantly 
decrease cell’s capacity to fix both double-strand break caused by drugs such as 
Irinotecan, Etoposide, as well as PARP inhibitors, and such increased drug 
sensitivity in cell is largely owing to their impaired capacity for HR repair (Alan and 
Ashworth, 2012). 
 
Regulation of BRCA1 in mammalian cells 
 
BRCA1 is regulated by poly-ubiquitination pathway 
          In Ruffner and Verma's report in 1997, BRCA1 was found undergoes 
hyperphosporylation during G1 and S phase and starts dephosphorylation 
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immediately after entering M phase, thus they concluded that BRCA1 is regulated 
during different stages of cell cycle in a qualitative and quantitative manner 
(Ruffner and Verma, 1997). Additionally, BRCA1's interaction and colocalization 
with other DNA damage response protein such as BRCA1 Associated Ring 
Domain 1 (BARD1) also exhibits a cell cycle dependent manner (Jin et al., 1997), 
so, it's clear that BRCA1's expression is tightly regulated both the transcriptional 
and protein level during different cell cycle stages, but very little is known about 
how BRCA1's protein stability is controlled.  
         Previous publications have identified that F-box protein 44 (FBXO44) 
mediates BRCA1's degradation in ubiquitination pathway by Skp1-Cul1-F-box-
protein 44 (SCFFBXO44) complex and such regulation is promoting the development 
of sporadic breast cancer (Lu et al.,2012). Furthermore, E3 ligase HERC2 can also 
specifically target BARD1-uncoupled BRCA1 and lead to the degradation of 
BRCA1 in ubiquitination pathway; the depletion of HERC2 significantly reduced the 
impact of the inactivation BARD1 and restored BRCA1 expression in vitro, 
suggesting that HERC2 plays an critical role in destabilizing BRCA1 and 
contributing to the breast carcinogenesis (Wu et al., 2010).  Interestingly, N-
terminus mediates the both binding between BRCA1 and SCFFBXO44, HERC2.  
 
HERC2 and ubiquitination-proteasome pathway 
          Degradation of proteins involve two successive steps: load poly-ubiquitin by 
covalent bonds to the targeted proteins and degradation of the proteins by 26S 
proteasome complex.  In general, the ubiquitination pathways start with the 
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activation of ubiquitin by E1 enzyme which is also known as ubiquitin-activating 
enzyme, then E2 enzyme (also is called as ubiquitin-conjugating enzyme, UBC) will 
lead the ubiquitin via thiol ester bond to bind the targeted proteins. The specific 
targeting of E3 ligase is realized by the unique recognition motif and E3 ligase will 
process the conjugation of ubiquitin to the targeted protein and facilitate the 
synthesis of the poly-ubiquitin chain in multiple cycles. Even in most cases, E2 
enzyme transfer the first ubiquitin moiety to the E3-bound substrate protein, and 
then conjugate the following ubiquitin moiety to bound the previous one, but RING 
finger targeted substrate allow E2 enzyme transfer the ubiquitin moiety directly to 
the substrate.  Finally, ubiquitin will be removed by deubiquitinating enzymes 
(DUBs) for recycle and ubiquitin-tagged proteins will be destructed into small 
peptides by the 26S proteasome complex (Glickman and Ciechanover, 2002) 
(Figure 5).  
             HERC2 gene is highly mutable and it was discovered from the deletion 
hotspot on human chromosome 15q11-q13, HERC2 gene encodes a large protein 
with a molecular weight of 528kDa (Lehman et al., 1998). Bioinformatics analysis 
indicated its highly conserved function domains include RCC1-like domain and 
COOH-terminal HECT domain, which are responsible for the Ran-dependent 
membrane trafficking and E3 ligase function respectively By mediating ubiquitin-
dependent recruitment of DNA damage repair proteins to damage chromosomes 
and form complex with RNF8, HERC2 facilitates E2 ligase UBC13 to conjugate 
with RNF8, in turn to regulate the expression levels of series repair proteins such 
as 53BP1 and BRCA1 (Bekker-Jensen et al., 2010). 
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Figure 1. Schematic Model for major DNA damage response kinase: ATM and 
ATR Activation 
 
(A) IR treatment forms DSBs and activates PARP1. Activation of the ATM 
activity by MRN and TIP60 leads to the phosphorylation of CHK2, p53, and the γ-
H2AX as well as downstream signaling cascade, which results in the recruitment of 
MDC1, RNF8, RNF168, BRCA1, and 53BP1 to damage sites (B) UV or replication 
stress lead to replication fork stalling and accumulation of RPA to coat on ssDNA, 
then ATR/ATRIP as well as RAD17/ RFC2-5 complexes will be recruited to 
damaged ssDNA. ATR kinase recruits the 911-associated protein TOPBP1 and 
leads to the activation of the ATR signaling cascade and downstream CHK1 
phosphorylation. Adapted from Ciccia and Elledge, Molecular Cell 40, 179-204 
(2010) with permission from Elsevier. 
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Functional role of NPRL2/TUSC4  in suppress tumor proliferation and 
maintain DNA damage response 
             Tumor Suppressor Candidate 4 (NPRL2/TUSC4) is also called Nitrogen 
Permease Receptor 2-like (NPRL2), and it was first identified from lung cancer 
homozygous deletion region which containing multiple tumor suppressor genes on 
chromosome 3p21.3. NPRL2/TUSC4 gene contains 3.3kb with 11 exons coding for 
a 1.5kb mRNA, and various splicing isoforms are expressed abundantly in normal 
lung and testis tissues, NPRL2/TUSC4 (red in figure) conserved across species 
ranging from yeast to chimpanzee with 33-66% aligned sequence (Figure 6). 
Sequencing data indicated 1 out of 40 lung cancer cell lines contains a frameshift 
mutation of NPRL2/TUSC4 gene which produces a stop codon (CAA to TAA Stop 
codon 261 in H1514 cell line), NPRL2/TUSC4 gene encodes a 43 kd soluble 
protein with an unknown protein binding domain (Lerman and Minna, 2000). In a 
follow up paper in 2002, exogenous expression of NPRL2/TUSC4 by adenovirus 
significantly inhibited the growth of Non Small Lung Cancer cell lines proliferation in 
vitro and the cancer development in vivo, it also increased the apoptotic cells in 
lung cancer cell lines which NPRL2/TUSC4 expression was originally disrupted, as 
the programmed cellular response to stress and stimuli, the decreased apoptosis is 
always considered as result of the inactivation of tumor suppressor, so these 
results suggested the important roles of NPRL2/TUSC4 are playing in the 
safeguard and maintenance of genomic stability ( Ji et al., 2002).  
             Additionally, inactivation of NPRL2/TUSC4 was found in multiple other 
cancer types including renal and cervical cancers (Li et al., 2004). NPRL2/TUSC4 
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was also found reciprocally correlated with the sensitivity of cisplatin (CDDP), a 
commonly used anti-cancer drug which containing platinum and cause apoptosis in 
cancer cells. Researchers reintroduced NPRL2/TUSC4 expression in 
NPRL2/TUSC4-null, cisplatin-resistant lung cancer cell line H322, and they were 
able to resensitize the response of cell to cisplatin and increased the apoptotic cell 
death, more specifically, the combination therapy with NPRL2/TUSC4-containing 
nano-particles and cisplatin significantly reduced the tumor size and inhibited cell 
proliferation compare to cisplatin treatment alone. This result indicated 
NPRL2/TUSC4's potential role to mediate the DNA damage response and the 
capacity to predict the clinical outcomes of cisplatin treatment in patients (Ueda at 
al., 2006).  The same research group published in 2010 again proved that the 
increased sensitivity to cisplatin in NPRL2/TUSC4-null lung cancer cell line was 
associated increased DNA damage response activities, reintroduction of 
NPRL2/TUSC4 into cells by nanoparticles not only increased p-ATM, p-CHK1, p-
CHK2, γ-H2AX phosphorylated protein levels, which indicated the activation of 
DNA damage response, but also showed that reintroduction of NPRL2/TUSC4 
arrested cells into G2/M phases after cisplatin treatment, suggested cells with 
NPRL2/TUSC4 would eventually undergo apoptosis process, which shed the light 
to overcome cisplatin resistance and promote clinical efficacy (Jayachandran et al., 
2010).    
              Based on sequencing and bioinformatics analysis, it was believed an 
unknown protein-binding domain was contained at the N-terminal of 
NPRL2/TUSC4 protein. In 2008, Kurata and his colleagues found that 
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NPRL2/TUSC4 can physically interact with 3-phosphoinositide-depedent protein 
kinase-1 (PDK1) and prevent the binding of its co-activator Src to bind its 
phosphorylation sites at tyrosine-9,-373 and -376 residues, thus inhibit the 
activation of PDK1 and abolish the activity of AKT pathway, the depletion of 
NPRL2/TUSC4 expression also promoted the cell proliferation (Kurata et al., 2008). 
Furthermore, NPRL2/TUSC4 can also form complex with NPRL3 and DEPDC5, 
the inhibition of this complex negatively regulate mTROC1 pathway and leading to 
cells become more resistance to amino acid deprivation, and such cells are 
hyperactive in term of growth and hypersensitive to mTROC1 inhibitor rapamycin, 
this paper confirmed the tumor suppresor role of NPRL2/TUSC4 in the 
maintenance of genome stability and regulation of cell as well as tumor growth 
(Bar-Peled et al., 2013). 
           These studies consistently described that the inactivation of NPRL2/TUSC4 
correlates with lower level of DNA damage response kinase activities and elevated 
cell proliferation, while overexpression of TUCS4 is associated with inhibition of 
tumor growth in various cancer types. Based on the accumulating evidences that 
NPRL2/TUSC4 plays tumor suppressor functions in vitro and in vivo to maintain 
genomic stability and inhibit tumorigenesis pathways by its binding domains, it's 
reasonable to suspect that NPRL2/TUSC4 deficiency would lead to a compromised 
DNA damage repair system such as HR repair and allow the potential increased 
sensitivity of cells to DNA damaging drugs and therapeutics. And most likely these 
regulation would occur through protein-binding regulation considering 
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NPRL2/TUSC4 doesn't contain the domains responsible for phosphorylation or 
other kinase activities. 
 
 
 
Figure 2. BRCA1 mutations and breast cancer.  
 
BRCA1 mutated women have 60% possibility to develop breast cancer before the 
age of 70, while BRCA2 mutated women have 40% possibility and normal BRCA1 
women have only 10%. Adapted from 
www.cancer.gov/cancertopics/factsheet/Risk/BRCA. 
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Figure 3.BRCA1 and its function network. 
 
BRCA1 is associated with multiple pathways including DNA repair, cell-cycle 
checkpoint regulation, ubiquitylation and transcriptional regulation. DNA damage 
response triggers BRCA1 activation. Several damage sensors, including ATM/ATR 
are activated in response to DNA damage. CHK2 is activated to prevent cell 
division by mediating phosphorylation of BRCA1 and p53. BRCA2 and RAD51 can 
form complex with FANCD2, then binds to BRCA1 and promotes S-phase or G2 
arrest. BRCA1 forms a heterodimer with BARD1 to activate the ubiquitin-ligase 
function. DNA repair by homologous recombination is mediated by the BRCA1-
associated surveillance complex which contains of BLM, MSH2–MSH6 and 
MRE11–RAD50–NBS1. BRCA1 has been also shown to mediate X-chromosome 
silencing, and also to mediate non-homologous end joining during DNA repair. 
BRCA1 can form complexes to mediate chromatin remodeling and homologous 
recombination. BRCA1 interacts with CHK1 to regulate apoptosis. 
Adapted from Narod and Foulkes Nature Reviews Cancer 4, 665-676 (2010) with 
permission from Elsevier. 
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Figure 4. Schematic Model for major homologous recombination (HR) and 
Non-homologous end-joining (NHEJ) repair. 
 
DSBs can be repaired by one of  two pathways: homologous recombination (HR)  
or non-homologous end joining (NHEJ). Both pathways require recruitment of 
MDC1 and the RNF8 as well as RNF168 ubiquitin E3 ligase to DNA damage sites.  
The difference between the two pathways is that HR repair requires BRCA1 while 
HNEJ repair is dependent on 53BP1 recruitment. In HR repair, the RAP80–BRCA1 
complex is recruited through 2 pathways: either it binds to K63-linked poly-ubiquitin 
chains attached to MDC1 or through interactions with hybrid SUMO-ubiquitin 
chains. Adapted from Lu and Matunis Nature Structural & Molecular Biology 12, 
1346-1348 (2013) with permission from Elsevier. 
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Figure 5. Ubiquitin signaling of DNA double-strand breaks.   
 
The signaling cascade of  ubiquitylation events. E3 ligases specifically target their 
substrates , examples are ( RING finger protein 8 (RNF8), HECT domain  and 
RCC1-like domain-containing protein 2 (HERC2), RNF168, BRCA1 and BRCA1-
associated RINg domain  protein 1 (BARD1)) as shown above. E2 enzymes are 
the ubiquitin-conjugating  enzyme  including UBC13, MMS2 and an unspecified E2.  
X and Y stands for unidentified ubiquitylation targets. While E1 enzyme which is 
also known as ubiquitin-activating enzyme is not shown above. 
Adapted from  Ulrich and Walden,  Nature Reviews Molecular Cell Biology 11, 479-
489 (2010) with permission from Elsevier. 
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Figure 6. NPRL2/TUSC4 gene tree. 
Human NPRL2/TUSC4 (red in figure) conserved across species ranging from yeast 
to chimpanzee with 33-66% aligned sequence. Image was generated by Ensembl 
genome browser , gene ID: ENSG00000114388 
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Chapter 2 
 
MATERIALS AND METHODS 
 
Cell cultures and plasmid  
The U2OS, MDA-MB-231, and MCF-10A cell lines were purchased from the 
American Type Culture Collection. McCoy’s 5A medium (CellGro;10-050-CV) 
supplemented with 10% fetal bovine serum was used to maintain U2OS cells, 
RPMI 1640 medium (Corning; 10-104-CV) supplemented with 10% fetal bovine 
serum was used to culture MDA-MB-231 cells, and serum-free mammary epithelial 
growth medium (Clonetics; CC-3051) containing insulin, hydrocortisone, epidermal 
growth factor, and bovine pituitary extract was used to maintain MCF-10A cells. All 
cells were incubated under humidified conditions in 5% CO2. The pCMV5-3 ×Flag 
vector plasmid was kindly provided by Dr. Funda Meric-Bernstam (The University 
of Texas MD Anderson Cancer Center). The MD Anderson DNA Sequencing and 
Microarray Facility confirmed the identities of all plasmids. 
 
Antibodies and reagents  
An anti-NPRL2/TUSC4 antibody was purchased from Proteintech (10157-1-AP), an 
anti-BRCA1 antibody was purchased from Santa Cruz Biotechnology (sc-6954), 
and anti-Flag M2 (F3165) and anti--actin (A2066) antibodies were purchased from 
Sigma. Anti-HERC2 antibodies were purchased from BD Biosciences (612366). 
MG132 was purchased from EMD Biosciences (133407-82-6), and cycloheximide 
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was obtained from Sigma (C7698). G418 was purchased from Sigma (A1720). 
Full-length NPRL2/TUSC4 was amplified using a TOPO TA cloning kit for 
subcloning (Invitrogen; 45064) with the sense primer for the sequence of 5'-
AATGGGCAGCGGCTGCCGCA-3' and anti-sense primer for the sequence of  5'-
TCACTTCCAGCAGATGATGA-3'. 
 
RNA Extraction and RT-PCR 
RNA was extracted by TRIzol reagent (Life Technologies; 15596026)  and reverse 
transcription was conducted using  SuperScript III kit (Invitrogen), and BRCA1 was 
amplified using RT-PCR with the sense primer 5'-CAGCGATACTTTCCCAGAGC-3' 
and anti-sense primer 5'-CTTGTTTCCCGACTGTGGTT-3'. Cyclophilin was used 
as internal control.  
 
RNA interference 
Stable knockdown of NPRL2/TUSC4 expression was established via RNA 
interference using lentiviral vector short hairpin RNA (Sigma; MISSION; 
NM660545). NPRL2/TUSC4 was targeted with a lentiviral particle of MISSION 
short hairpin RNA as well as MISSION nontargeted control particles. Western 
blotting was performed after transduction to confirm the knockdown efficiency, and 
puromycin was added to U2OS cell medium to maintain the NPRL2/TUSC4-
knockdown specificity. For transient transfection, human NPRL2/TUSC4 siRNA 
was purchased from Thermo Scientific (On-Target; 10641), and the NPRL2/TUSC4 
target siRNA  sequences were GCAUCGAACACAAGAAGUA and 
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GACCCAAGAUCACCUAUCA. Human BRCA1 siRNA was purchased from 
Thermo Scientific (On-Target; J-003461-09), and the BRCA1 target sequence was 
CAACAUGCCCACAGAUCAA. Human HERC2 siRNA was purchased from 
Thermo Scientific (On-Target; J-007180-09, J-007180-10, J-007180-11, and J-
007180-12), and the HERC2 target sequences were 5'-
GCACAGUAUCACAGGUA-3', 5'-CGAUGAAGGUUUGGUAUUU-3', 5'-
GAUAAUACGACACAGCUAA-3', and 5'-GCAGAUGUGUGCUAAGAUG-3', 
respectively. 
 
Immonuprecipitation and Immunoblotting 
For immunoprecipitation of HERC2, BRCA1, and NPRL2/TUSC4, U2OS cells were 
first transfected with an empty vector or FLAG-NPRL2/TUSC4 plasmids. After 72 h 
of transfection, G418 was added to the medium for selection purposes. After stable 
clones were isolated from the pool, whole cellular extracts were incubated with 
RIPA buffer as described previously (Pierce et al,. 1999), and the products were 
immunoprecipitated with an anti-FLAG M2 Affinity gel (Sigma; A2220) for 8 h at 
4°C. After washing, the complexes were eluted with 3×FLAG peptide and 
evaluated using sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis 
(PAGE). For immunoprecipitation of the binding between HERC2 and BRCA1, cell 
lysates were precleared with A/G Agarose beads (Santa Cruz Biotechnology; SC-
2003) and incubated with 1 g of antibody at 4 °C overnight. Precipitates were then 
washed and suspended in 5× SDS buffer and submitted to SDS-PAGE and 
immunoblotting. For immunoblotting, after samples were separated using 
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electrophoresis, membranes were blocked with 5% milk diluted in Tris buffer with 
0.1% Tween 20 for 1h at room temperature. The primary antibody was diluted in 
5% bovine serum albumin in phosphate-buffered saline with sodium azide (Sigma; 
S227) and then incubated with the membranes for 2 h at room temperature. 
Subsequently, membranes were washed with phosphate-buffered saline with 0.1% 
Tween 20 and incubated with secondary antibody. Finally, signals of the bound 
antibody were detected using enhanced chemiluminescence (GE Healthcare; 
RPN2232). 
 
In vitro proliferation and PARP inhibition assays  
MTT (Sigma; M5655) was used to evaluate the proliferation of cells. Briefly, cells 
were counted and seeded in a 96-well flat-bottomed plate. After 96 h, cells were 
incubated with MTT substrate (Sigma; 20 mg/ml) for 4 h, and the cultures were 
removed and replaced with dimethyl sulfoxide. The optical density was measured 
spectrophotometrically at 570 nm. The colony formation assay was performed by 
seeding 200 cells in six-well plates. Olaparib and rucaparib were added to the 
culture medium, and the cells were compared with untreated control cells. Colonies 
were scored after 3 weeks. All experiments were repeated three times. 
 
Microarray analysis  
mirVana RNA isolation kit (Ambion) was used to isolate total RNA. Five hundred 
nanograms of total RNA were used with a Sentrix Human-6 Expression Bead Chip 
(Illumina) for labeling and hybridization. BeadArray Reader was used for chip 
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scanning (Illumina). As described previously (Peng et al., 2014), the gene 
expression profile was subjected to normalization and log2 transformation. The 
NextGENe software program was used to identify genes whose expression differed 
in two clusters, and a t-test was used to separate genes with significantly different 
expression (P < 0.001). The Ingenuity Pathway Analysis system was used for gene 
enrichment analysis. 
 
Homologous recombination repair and flow cytometry analyses  
The plasmids DR-GFP, pCAGGS, and pCBASce were gifts from Dr. Maria Jasin 
(Memorial Sloan-Kettering Cancer Center). U2OS cells were first treated with 
NPRL2/TUSC4 and BRCA1 siRNA as well as control siRNA for 24 h. BRCA1-
containing plasmids were then transfected into NPRL2/TUSC4-knockdown cells to 
induce re-expression of BRCA1. After 48-72 h, flow cytometry was performed to 
detect GFP-positive cells using a FACSCalibur and the CellQuest software 
program (Becton Dickinson). Three independent experiments were performed to 
obtain mean values and their standard deviations. Cell-cycle analysis was 
performed at the MD Anderson Cancer Center Flow Cytometry and Cellular 
Imaging Facility. 
 
Tumor growth in nude mice and immunohistochemistry  
Six-week-old female nude mice were used in this study. The MD Anderson 
Institutional Animal Care and Use Committee approved the animal protocol. 5 × 106 
MDA-MB-231 cells with and without NPRL2/TUSC4 overexpression or 1 × 107 
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MCF-10A cells with and without knockdown of NPRL2/TUSC4 expression were 
injected to the mammary fatpads of mice. Tumors were measured from 1 week 
after MDA-MB-231 cells injection and monitored weekly, whereas MCF-10A tumors 
were observed 1 month after cell injection. At least five nude mice were used for 
each group. Human breast tissue samples (Biomax) were embedded in Xylene and 
100%, 95%, 70%, 50% ethanol respectively for deparaffinization, slides were then 
incubated with NPRL2/TUSC4 antibody at 4º overnight followed by antigen 
retrieval. Then samples were processed and evaluated immunohistochemically 
under microscope after being dehydrated and stabilized. 
 
Transfection and ubiquitination assay 
 U2OS cell transfection was conducted using Oligofectamine (Life Technologies; 
12252-001). Plasmids encoding HA-tagged ubiquitin were transfected in U2OS 
cells with and without knockdown of NPRL2/TUSC4 expression. Forty-eight hours 
after transfection, cells were harvested and lysed with RIPA buffer. Cell lysates 
were then incubated with Ni2+ beads (Amersham Pharmacia Biotech) to pull down 
histidine-tagged BRCA1 with the beads. Precipitated BRCA1 protein was isolated 
using SDS-PAGE and detected using an anti-HA antibody (Sigma; ab18181). 
 
Immunoflurosence foci staining 
Cells were cultured on cover slips in 6-well plates before staining for 24 hours, then 
growth medium was removed and cells were washed by ice-cold PBS twice. Then 
cells were incubated by cytoskeleton buffer (10mM PIPES, Ph6.8, NaCl 100mM, 
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Sucrose 300mM, MgCl2 3mM, EGTA 1mM,Triton X100/ 0.5%) for 3 min on ice, 
then cells were washed with PBS for 3 times and incubate  in stripping buffer (Tris 
HCL 10mM, NaCl 10mM, MgCl2 3mM, Tween 20/1%, Sodium deoxychalate 0.25%) 
for 3 min on ice. After wash with PBS for 3 times, cells were then fixed in 4% PFA 
overnight at 4 degrees.  After that, cells were permeabilized in 1% Triton X-100 and 
0.5% NP-40PBS for 30 mins and blocked in 5% horse serum/1% goat serum 
mixture for 1 hour at room temperature. Samples were incubated with primary 
antibody  in blocking buffer for 2 hours at room temperature, followed by 0.01% 
Triton-PBS wash and Fluor 488 and 594 conjugated secondary antibody (Life 
Technologies, 1:500) incubation for 1 hour at room temperature. Lastly, samples 
were mounted with DAPI antifade medium for microscope analysis.   
 
Microscopy analysis  
DNA damage foci staining images were captured with fluorescent microscope 
(Nikon, Eclipse E800). 60X oil objective lens (Plan Fluor, NA 1.3) and CCD camera 
(QImaging, Qiclick F-M-12) were equipped to facilitate the analysis and images 
capture were processed by the Nikon NIS-Elements system. 
 
 
HU recovery and checkpoint assay 
 
Cells were incubated in medium with or without HU (2 mM) for 24 hours. Then HU 
was removed, and cells were harvested at 0, 8, and 16 hours after release. 
Harvested cells were fixed in ethanol, stained with propidium iodide, and analyzed 
by FACS. For HU followed by Taxol, cells were untreated or treated with HU (2 
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mM) for 24 hours. Then HU was removed by replacing fresh medium, Taxol was 
added and harvested cells at 0, 8, 16 hours, cells were then fixed in ethanol and 
stained using phospho-histone H3 (Ser10)-specific antibody (p-H3) and propidium 
iodide (PI). 
 
Statistical Analysis 
All statistical analyses were performed with a two-tailed Student's t-test. 
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CHAPTER 3 
NPRL2/TUSC4 REGULATES BRCA1'S STABILITY BY BLOCKING ITS 
PHYSICAL INTERACTION WITH HERC2 
 
Results 
NPRL2/TUSC4 expression is reduced in breast cancer and correlates with 
breast cancer progression  
           To characterize whether NPRL2/TUSC4 expression is associated with 
breast cancer, we performed Western blotting to measure the expression of 
NPRL2/TUSC4 in non-transformed breast cell lines, including HMEC, MCF-10A, 
and MCF-12A, and breast cancer cell lines with both luminal and basal subtypes 
(Figure 7A). We observed that NPRL2/TUSC4 expression was markedly higher in 
the non-transformed cell lines than that in breast cancer cell lines. We also 
evaluated NPRL2/TUSC4 expression in normal breast tissue and breast 
carcinomas using immunohistochemical staining, and found that NPRL2/TUSC4 
expression was lower in the tumors than that in matched adjacent normal breast 
tissue (Figure 7B). Furthermore, The Cancer Genome Atlas-based analysis of 
mRNA expression in invasive breast carcinomas demonstrated a significant 
difference between the survival rates in patients with unaltered NPRL2/TUSC4 
expression and those with downregulated NPRL2/TUSC4 expression (P = 
0.000005).  Specifically, the survival rate of 100 months was 24.7% in 889 patients 
with downregulation of NPRL2/TUSC4 expression (Z-score threshold, ±1), while 
the survival rate in these patients dropped sharply to 0% after 100 months. In 
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comparison, the survival rate was 40% in patients with unaltered NPRL2/TUSC4 
expression after 200 months, with a P value less than 0.0001 (Figure 8A). 
Comparison of patients with upregulated and unaltered NPRL2/TUSC4 expression 
did not demonstrate any significant differences in survival rate (Figure 8B). Total of 
889 breast carcinoma patients has 65.20% without TUSC4 alteration, 24.70% with 
TUSC4 level down-regulation, 9.40% up-regulation and 0.6% mutation (Figure 8C). 
These results strongly suggested that low NPRL2/TUSC4 expression is associated 
with the cancer phenotype, indicating that NPRL2/TUSC4 may play an important 
role as a tumor suppressor in breast cancer patients. Based on the sequencing 
data of first 467 patients, there were 79 basal-like breast carcinoma patients, 203 
luminal A patients and 112 luminal B patients which account for 16.9%, 43.5%, 
24% of the total patients number respectively. Further sequencing data is 
necessary to complete the subtypes profiles for the rest of the patients. Future 
studies will need to establish the relationship between TUSC4 expression level and 
different breast cancer subtypes in terms of patients' survival rates.  
To systematically evaluate the tumor-suppressive function of 
NPRL2/TUSC4, we performed microarray analysis comparing NPRL2/TUSC4-
knockdown cell lines and control cell lines (Figure 9B). We then examined the 
differentially expressed genes in these cells using the Ingenuity Pathway Analysis 
system (QIAGEN). Comparison of the NPRL2/TUSC4-knockdown and control cells 
ranked cancer as one of the top disease and disorder pathways, further suggesting 
that NPRL2/TUSC4 functions as a tumor suppressor gene (Figure 9C). 
Additionally, high portion of genes in NPRL2/TUSC4-deficient gene signatures 
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were involved in canonical pathways such as DNA damage response and breast 
cancer regulation (Figure 9D). 
Owing to the low NPRL2/TUSC4 expression in breast cancer and the 
association with poor breast cancer patient survival rates, we explored the role of 
NPRL2/TUSC4 in the development of breast cancer and the possible functional 
pathways that NPRL2/TUSC4 is involved in. It has been previously reported that 
multiple cancers have mutations in or epigenetically silenced HR related genes, 
which indicated potential association between HR repair deficiency and cancer 
development (Deng and  Wang 2003; Lord and Ashworth 2002 ). Thus, we 
suspected that low expression of NPRL2/TUSC4 contributes to the deficiency of 
HR repair, which also drives genomic instability in breast cancer development. We 
performed a cluster analysis of a NPRL2/TUSC4-knockdown microarray signature 
with previously established HR repair deficiency (HRD) gene signatures (Peng et 
al, 2014). The heat map demonstrated that NPRL2/TUSC4-deficient cells formed a 
cluster with HRD gene signatures (Figure 9A), whereas the control cells separated 
from NPRL2/TUSC4-knockdown samples. Considering the fact that the HRD 
signature described above was discovered under the condition of loss of tumor 
suppressor BRCA1, the results suggested a potential correlation and molecular 
similarity between NPRL2/TUSC4 knockdown cells and BRCA1-deficient HR repair 
deficiency. 
By analyzing the well defined triple negative breast cancer cell lines makers, 
we also identified that NPRl2/TUSC4 has lower expression in basal-like cell lines 
compare to luminal types (Figure 9 E,F). Furthermore, RPPA analysis indicated 
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knockdown of TUSC4 U2OS cells exhibited similar gene clusters with BRCA1 
knockdown cells compare to control cells (Figure 9G). 
 
NPRL2/TUSC4 is widely expressed in both cytoplasm and cellular nucleus 
        We next examined the distribution of NPRL2/TUSC4 in cells. First, by damage 
foci staining, we found NPRL2/TUSC4 can form DNA damage foci in cells after 
both IR and UV, indicated the potential functions of NPRL2/TUSC4 in DNA 
damage response pathways (Figure 10). Additionally, chromatin fractionation 
assay indicated NPRL2/TUSC4 is widely distributed in both cytoplasm and 
nucleus, furthermore, data also identified NPRL2/TUSC4 is a chromatin binding 
protein, further suggested its possible functions in DNA damage response (Figure 
11). 
 
NPRL2/TUSC4 knockdown impairs HR repair by downregulation of BRCA1 
expression 
         The major conserved pathway used in mammalian cells to maintain genetic 
integrity and DNA fidelity is HR repair (Sung and Klein 2006; Lieber et al., 2003). 
Here, we have identified an association between expression profile of 
NPRL2/TUSC4 knockdown and BRCA1 deficient HRD gene signature. We 
suspected that loss of NPRL2/TUSC4 will also affect the foci formation of BRCA1, 
so we carried out phenotypic examination to test whether NPRL2/TUSC4 is 
required for BRCA1 foci formation by immunostaining. We performed BRCA1 foci 
staining followed by IR and UV irradiation. NPRL2/TUSC4 knockdown significantly 
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demolished the BRCA1 foci formation after irradiation, whereas control small 
interfering RNA (siRNA) did not affect the formation of BRCA1 foci (Figure 12, 13). 
We further evaluated HR repair efficiency by the standard HR repair analysis 
system (Pierce et al, 1999; Peng et al., 2009) with NPRL2/TUSC4-deficient U2OS 
model cells.  More specifically, the DR-GFP reporter substrate was incorporated 
into cellular genomic DNA. SceGFP contains an I-SceI endonuclease site within 
the coding region, which abolishes GFP expression. iGFP is a truncated GFP, 
which contains homologous sequence for the SceGFP. Expression of I-SceI 
induces a single DSB in the genome. in normal cells, this DSB can be repaired by 
HR repair , the expression of GFP can be restored, while in HR deficient cells, the 
DSB cannot be repaired, the expression of GFP will be significantly reduced and 
analyzed by flow cytometry to indicate the efficiency of HR repair (Figure 14B). We 
found that NPRL2/TUSC4-knockdown cells had a significant decrease of HR 
reporter activity compared to control cells, which suggested impaired HR repair 
efficiency (Figure 14A). We used BRCA1-knockdown cells as a positive indicator of 
homologous recombination repair to confirm the HR repair efficiency. 
NPRL2/TUSC4-knockdown cells presented comparative reduction in HR repair 
efficiency as BRCA1-knockdown cells, which were around 40-50% lower than that 
in control cells.  To confirm that the defective HR repair efficiency was not caused 
by transfection efficiency or inaccurate efficiency from I-SceI, we reintroduced 
BRCA1 expression into the NPRL2/TUSC4-knockdown cells and observed a 
significant increase in HR repair efficiency over that in NPRL2/TUSC4-knockdown-
only cells (P < 0.05).  
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Surprisingly, we found that knockdown of NPRL2/TUSC4 expression 
reduced the BRCA1 protein expression (Figure 14C), indicating that the decrease 
in HR repair efficiency in the NPRL2/TUSC4 knockdown cells may have resulted 
from abnormal BRCA1 protein expression. These results are consistent with our 
above findings that NPRL2/TUSC4-knockdown cells have HRD gene expression 
patterns similar to those in BRCA1-deficient cells which were used to generate our 
HRD gene signatures. These results revealed for the first time a novel function of 
NPRL2/TUSC4 in that disruption of its expression decreases BRCA1 expression 
and functions. Furthermore, BRCA1 and NPRL2/TUSC4 knockdown significantly 
reduced the HR repair efficiency compare to control, while NPRL2/TUSC4 
knockdown with BRCA1 overexpression restored the HR repair, double knockdown 
of both genes further reduced HR repair efficiency (Figure 27).  
        Additionally, about 1% of patients carry BRCA1 mutation, and the log-odds 
ratio between BRCA1 mutation and down-regulated NPRL2/TUSC4 is 0.875, which 
indicates the tendency of co-occurrence. However, the p-value is 0.102, suggesting 
there in no significant correlation. Thus, the BRCA1 mutation and down-regulated 
NPRL2/TUSC4 are not mutually exclusive nor co-occurring. 
 
NPRL2/TUSC4 regulates BRCA1 protein stability 
         We then investigated whether BRCA1 mutation is associated with 
NPRL2/TUSC4 expression level, as we expected, NPRL2/TUSC4 is not correlated 
with BRCA1 mutation in breast cancer patients (Figure 15A).  We next sought to 
determine how NPRL2/TUSC4 affects BRCA1 protein expression. To that end, we 
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first sought to determine whether reduced BRCA1 protein expression after 
NPRL2/TUSC4 knockdown was caused by altered cell-cycle distribution because 
BRCA1 expression has known to be cell-cycle regulated. We carried out a cell-
cycle analysis and did not observe a significant difference in G1-, G2/M-, or S-
phase distribution between control and NPRL2/TUSC4-knockdown cells (Figure 
15B), indicating that decreased BRCA1 expression after NPRL2/TUSC4 
knockdown was not resulted from the cell-cycle shift. To further determine whether 
such changes occur through transcriptional regulation, we performed quantitative 
reverse transcriptase-polymerase chain reaction to measure the BRCA1 mRNA 
expression in control cells and cells with NPRL2/TUSC4 knockdown. We identified 
no significant BRCA1 mRNA differences after NPRL2/TUSC4 knockdown (Figure 
15C), thus ruling out the possibility that BRCA1 expression by NPRL2/TUSC4 was 
regulated at the mRNA level. 
Next, we sought to determine if NPRL2/TUSC4 regulates BRCA1 protein 
stability. To answer this question, we conducted BRCA1 protein stability 
experiments by treating control and NPRL2/TUSC4-knockdown U2OS cells with 
cycloheximide, for the purpose of blocking protein synthesis. As shown in Figure 
16A, NPRL2/TUSC4 knockdown reduced the half-life of BRCA1 from about 20 h to 
less than 6 h, suggesting that NPRL2/TUSC4 plays an essential role in stabilizing 
BRCA1 at the protein level (Figure 16 B,C). Additionally, to determine whether 
BRCA1 protein stability is regulated by NPRL2/TUSC4 via the proteasome 
pathway, we treated control and NPRL2/TUSC4-knockdown U2OS cells with the 
proteasome inhibitor MG132. As shown in Figure 17, MG132-based treatment 
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restored the BRCA1 expression in cells with NPRL2/TUSC4 knockdown but only 
slightly increased the BRCA1 protein expression in control cells. This result 
suggested that NPRL2/TUSC4 regulates BRCA1 protein stability via the 
proteasome-dependent pathway. 
 
NPRL2/TUSC4 regulates BRCA1 protein stability via ubiquitination pathway 
It has been previously reported that HERC2 is an E3 ligase that targets BRCA1 for 
degradation (Jin et al., 1997). To determine whether NPRL2/TUSC4 regulates 
BRCA1 stability via HERC2, we performed ubiquitination assay by transfecting 
hemagglutinin (HA)-tagged ubiquitin plasmids into cells with or without 
NPRL2/TUSC4 knockdown, followed by immunoprecipitation with control IgG or an 
anti-BRCA1 antibody. Surprisingly, we observed no signs of ubiquitination 
regardless of the NPRL2/TUSC4-knockdown status. However, after treatment with 
MG132, Western blotting for HA-tagged ubiquitin showed that NPRL2/TUSC4-
knockdown cells underwent heavy ubiquitination, whereas control cells exhibited 
only a light polyubiquitination ladder (Figure 18), indicating that knockdown of 
NPRL2/TUSC4 expression caused a robust increase in BRCA1 protein 
polyubiquitination. We also confirmed previous findings that downregulation of 
expression of HERC2 led to increased expression of BRCA1 regardless of the 
presence of NPRL2/TUSC4 (Figure 19A, B). Under both conditions, BRCA1 
expression was markedly upregulated after depletion of HERC2. 
The next question to be answered was whether NPRL2/TUSC4 participates 
in ubiquitination of BRCA1 via HERC2 indirectly or stabilizes BRCA1 directly. We 
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performed immunoprecipitation with established NPRL2/TUSC4-overexpressing 
U2OS cell lines to determine the relationships among NPRL2/TUSC4, BRCA1, and 
HERC2. Reciprocally, we found that NPRL2/TUSC4 physically interacts with 
HERC2 but not with BRCA1 (Figure 20), which strongly suggested that 
NPRL2/TUSC4 regulates BRCA1 stability via interaction with HERC2. Considering 
the previously reported binding functions of NPRL2/TUSC4 (Ueda et al., 2006; 
Jayachandran et al, 2010) (Figure 22), we suspected that NPRL2/TUSC4 may 
prevent physical interaction between BRCA1 and HERC2. The binding between 
these two proteins (Wu et al, 2010) has been previously described, so we 
performed further immunoprecipitation to determine whether overexpression of 
NPRL2/TUSC4 weakens this binding. As shown in Figure 21, endogenous HERC2 
physically bound to BRCA1. Intriguingly, overexpression of NPRL2/TUSC4 
interrupted the binding between HERC2 and BRCA1, indicating that 
NPRL2/TUSC4 may regulate BRCA1 stability by preventing physical interaction 
between BRCA1 and HERC2.  Additionally, BRCA1 expression level is negatively 
associated with HERC2 expression level in breast cancer cell lines (Figure 27). 
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Figure 7.  Low NPRL2/TUSC4 expression level in breast cancer  
A. Lower NPRL2/TUSC4 expression levels was found in both luminal and   
basal types of breast cancer cell lines, while non-transformed breast cell  
lines (HMEC, MCF-10A and MCF-12A) exhibited higher NPRL2/TUSC4  
level. 
B. IHC staining indicated normal breast tissue (left) expressed higher 
NPRL2/TUSC4 protein level than breast cancer tissues (right), and bar  
graphs also indicated the quantified NPRL2/TUSC4. 
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Figure 8.  Low NPRL2/TUSC4 expression level is associated with poor 
survival rate  
A. 24.7% breast cancer patients showed low NPRL2/TUSC4 expression level, and 
the low NPRL2/TUSC4 level correlates with poor survival rate (p=0.00005, data 
adapted from cBio portal for Cancer Genomics). B.9.4% of up-regulation of 
NPRL2/TUSC4 expression patients out of 889 in total didn’t show significant 
change of survival rate compared to TUSC4 non-altered patients, with p value of 
0.672; C.total of 889 breast carcinoma patients has 65.20% without NPRL2/TUSC4 
alteration, 24.70% with NPRL2/TUSC4 level down-regulation, 9.40% up-regulation 
and 0.6% mutation. 
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Figure 9. NPRL2/TUSC4 is associated with HR defect genes and breast 
cancer phenotypes. 
A. NPRL2/TUSC4 knockdown microarray gene expression profiles were clustered 
with previously identified 230 homologous recombination defect gene signature, 
genes with p<0.001 and log ratio 0.1 were separated to generate heat map 
between NPRL2/TUSC4 knockdown cells and control cell lines. 
B. Gene expression analysis identifies NPRL2/TUSC4 knockdown gene signature. 
The analysis was performed using NexusExp3 array tools. Heat map of the 
NPRL2/TUSC4 knockdown gene signature, consisting of 263 genes whose 
expression differed from control cell lines. Microarray was conducted in three 
independent samples of control cells and three independent samples of 
NPRL2/TUSC4 knockdown cell line. Student’s t-test was conducted between the 
average of control cells and that of knockdown cells (p<0.00001).  
C. IPA analysis of NPRL2/TUSC4 knockdown cells' top pathways changed. 
D. Top canonical pathways in terms of number of genes in NPRL2/TUSC4-
deficient gene signature on analysis with Ingenuity Pathway Analysis Software. 
Genes with ±1.25 fold change and p value less than 0.05 were selected and 
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imported into IPA system. Significance refers to the log (p value), which was 
calculated by IPA program using Fisher’s exact test. Threshold is at p= 0.05. 
E. NPRL2/TUSC4 is associated with different phenotypes of breast cancer cell 
lines. 
F. Low NPRL2/TUSC4 expression level is associated with breast cancer 
phenotypes. Normal or non-transformed breast cell lines has relatively higher 
expression level than luminal and basal-like breast cancer cell lines, the p value is 
less than 0.05.  
G. RPPA analysis indicated NPRL2/TUSC4 knockdown cells shared similar cluster 
patterns with BRCA1 knockdown cells. 
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Figure 10. NPRL2/TUSC4 forms DNA damage foci after irradiation 
NPRL2/TUSC4 forms DNA damage foci after both types of irradiation in U2OS 
cells, under the conditions of both IR and UV, while the foci were not observed in 
the NPRL2/TUSC4 knockdown cells, as well in the non treated cells. 
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Figure 11. NPRL2/TUSC4 widely spreads in both cytoplasm and nuclear 
Nuclear fractionation definitions are described below, F1-Cytoplasm, F2- Washing 
supernatant from Cytoplasm, F3-Soluble Chromatin proteins, F4-Chromatin bound 
proteins. U2OS control and NPRL2/TUSC4 Flag tag overexpression cells were 
used from left to right. 
 
 
 
 
 
- 45 - 
 
 
 
 
Figure 12. NPRL2/TUSC4 knockdown reduced BRCA1 protein foci after UV 
NPRL2/TUSC4 knockdown reduced BRCA1 foci formation after UV, while control 
cells (NT) didn’t have such effect. p-RPA indicated the efficiency of irradiation. 
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Figure 13. NPRL2/TUSC4 knockdown reduced BRCA1 protein foci after IR 
NPRL2/TUSC4 knockdown reduced BRCA1 foci formation after IR, while control 
cells didn’t have such effect (NT). γ-H2AX indicated the efficiency of irradiation. 
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A. 
 
 
B. 
NPRL2/TUSC4 knockdown reduced HR repair efficiency and BRCA1 protein 
expression level  
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Figure 14. NPRL2/TUSC4 knockdown reduced HR repair efficiency and 
BRCA1 protein expression level 
A. NPRL2/TUSC4 knockdown significantly reduced HR repair efficiency compared 
to control (p<0.05), while reintroduction of BRCA1 expression into 
NPRL2/TUSC4-knockdown cells rescued the HR repair efficiency (p<0.05). 
B. Simplified schematic of the DR-GFP reporter assay for HR repair,  Adapted 
from  Lutzmann,  Molecular Cell 47, 523--534 (2012) with permission from 
Elsevier. 
C. Western blotting confirmed NPRL2/TUSC4, BRCA1 knockdown and 
overexpression of BRCA1 after NPRL2/TUSC4 knockdown. BRCA1 intensity 
normalized to NPRL2/TUSC4 was measured by Image J. 
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Figure 15.  NPRL2/TUSC4 knockdown decreased BRCA1 is not through cell 
cycle distribution  
A. BRCA1 mutation is not associated with NPRL2/TUSC4 expression level. Data 
was generated from database Oncomine, Pawitan breast cancer cell samples; 
B. Knockdown of NPRL2/TUSC4 didn’t significantly change the cell cycle 
distribution of U2OS cells compared to control cells. G1, G2/M and S phases cells 
were indicated by percentage of total cell numbers.  
C. NPRL2/TUSC4 knockdown cells didn’t show significant decrease of BRCA1 
mRNA by qRT-PCR compared to control cells. The values of each column were 
normalized to the value of cyclophilin. 
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Figure 16. Knockdown of NPRL2/TUSC4 decreased BRCA1 stability in CHX 
assay 
A. NPRL2/TUSC4 knockdown U2OS cells showed shortened half-life of BRCA1 
level compared to control cells. All cells were treated with 1μM of CHX for 0 to 
24 hours. 
B. Curves of BRCA1 level normalized to 0h after CHX treatment, while blue curves 
indicated control cells, and red curves indicated NPRL2/TUSC4 knockdown 
cells. 
C. Bar graph of BRCA1 half-life. Control cells have BRCA1 half-life about 20 hours, 
while NPRL2/TUSC4 knockdown cells have BRCA1 half-life about 5 hours. 
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Figure 17. NPRL2/TUSC4 regulates BRCA1 stability via proteasome 
degradation pathway 
NPRL2/TUSC4 knockdown U2OS cells showed shortened half-life of BRCA1 level 
compared to control cells. All cells were treated with 1μM of CHX for 0 to 24 hours. 
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Figure 18. NPRL2/TUSC4 regulates BRCA1 stability via ubiquitination 
pathway 
NPRL2/TUSC4 knockdown increased ubiquitination level of BRCA1 compared to 
control cells (After MG132 enrichment for ubiquitination). 
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Figure 19. HERC2 is E3 ligase to regulate BRCA1's stability 
A. HERC2 knockdown rescued BRCA1 expression level, with and without the 
presences of NPRL2/TUSC4. 
B. Bar graph indicated a significant BRCA1 reduction after NPRL2/TUSC4 
knockdown (p<0.05), BRCA1 increases after HERC2 knockdown with 
NPRL2/TUSC4 presence (p<0.05), or without NPRL2/TUSC4 (p<0.001). All 
values were compared to control cells. 
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Figure 20. NPRL2/TUSC4 physically interacts with HERC2 but not BRCA1 
3XFlag control and NPRL2/TUSC4-Flag tag U2OS cells were used to perform 
Immunopercipitation. Total of 4mg of protein were used in each IP conditions, and 
2% input were loaded as control and indicate the overexpression of TUSC4. 
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Figure 21. NPRL2/TUSC4 overexpression reduced the binding between 
BRCA1 and HERC2 
NPRL2/TUSC4 overexpression reduced the binding between BRCA1 and HERC2 
in Hela cell lines. 2% input were used to indicate the level of HERC2, IgG control 
antibody and BCRA1 antibody were used to perform IP in both control cells and 
NPRL2/TUSC4 overexpression cells. Total of 4mg of protein were used to perform 
in each condition. 
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Figure 22. BRCA1 interacts with HERC2 and HERC2 regulates BRCA1 
depends on BRAD1 
A. BRCA1 physically interacts with HERC2 regardless of the irradiation.             
B. HERC2 degrades BARD1-uncoupled BRCA1 in the CHX treatment, BRCA1 is 
destabilized while BARD1 is deficient; and BRCA1 is stabilized when HER2 is 
depleted.  Adapted from Wu et al.,  Cancer Research  70, 6384-6392 (2010) with 
permission from Elsevier. 
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Figure 23. Simplified model of the mechanism NPRL2/TUSC4 stabilizes 
BRCA1 
When NPRL2/TUSC4 is depleted in breast cancer, HERC2 has increased binding 
to BRCA1, thus ubiquitinates BRCA1 and degrades in proteasome-depedent 
pathway; while TUSC4 is overexpressed, TUSC4 prevents the binding between 
HERC2 and BRCA1, thus stabilize BRCA1.  
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Figure 24. Predicted model of the mechanism NPRL2/TUSC4 stabilizes 
BRCA1 through BARD1 
When NPRL2/TUSC4 is depleted in breast cancer, HERC2 has increased binding 
to BRCA1/BARD1 complex, thus ubiquitinates BRCA1 and degrades in 
proteasome-depedent pathway; while NPRL2/TUSC4 is overexpressed, TUSC4 
prevents the binding between HERC2 and BRCA1, and enhances the 
BRCA1/BARD1 binding.  thus stabilize BRCA1.  
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Figure 25.  NPRL2/TUSC4 and BRCA1 double knockdown further reduced HR 
repair efficiency. 
 
A.  BRCA1 and NPRL2/TUSC4 knockdown significantly reduced the HR repair 
efficiency compare to control, while NPRL2/TUSC4 knockdown with BRCA1 
overexpression restored the HR repair, double knockdown of both genes further 
reduced HR repair efficiency. 
B. Western blot confirmed the NPRL2/TUSC4 and BRCA1 knockdown efficiency 
and overexpression level of BCRA1. 
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Figure 26. NPRL2/TUSC overexpression is associated lower breast cancer 
proliferation rates 
 
NPRL2/TUSC4-flag tag overexpression exhibit significant slower proliferation rates 
in both MDA-AB-231 cell line and MCF-7 cell line. In 231 cells, clone #7 and #13 
were used to compare with 3xF flag control in both MTT and colony formation 
assay(upper panel); In MCF7 cells, clone #1 and #4 were used to compare with 
3xF flag control in both MTT and colony formation assay(lower panel) 
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Figure 27. BRCA1 expression level is negatively associated with HERC2 
expression level in breast cancer cell lines. 
 
MDA436, SCBR3, HCC1937,MDA231,T47D, MCF7, MCF12A, HMEC and 
MCF10A were used to conduct the western blot; expression level of BRCA, 
HERC2 were evaluated, and tublin were used as loading control. 
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CHAPTER 4 
 
NPRL2/TUSC4 FUNCTIONS AS TUMOR SUPPRESSOR PROTEIN IN BREAST 
CANCER 
RESULTS 
NPRL2/TUSC4 suppresses the tumorigenicity of human breast cancer cells 
             We have identified NPRL2/TUSC4 functions as tumor suppressor gene in 
breast cancer, possibly through positively regulating BRCA1. Next, we postulated 
that overexpression of NPRL2/TUSC4 also suppresses breast tumor proliferation in 
vitro and in vivo. To validate this, we compared the proliferation rate of the breast 
cancer cell line MDA-MB-231 with or without NPRL2/TUSC4 overexpression. 
Colony formation assays indicated markedly reduced proliferation of the 
NPRL2/TUSC4-overexpressing cells (Figure 26, 30). Because NPRL2/TUSC4 
effectively inhibits breast cancer cell growth in vitro, we further examined the effect 
of NPRL2/TUSC4 overexpression in a xenograft mouse model of breast cancer. 
We injected female mice with control or NPRL2/TUSC4-overexpressing MDA-MB-
231cells into the mammary fatpads. We then monitored and measured tumor 
growth weekly. By week 6 after injection, 5 of 10 mice injected with 
NPRL2/TUSC4-overexpressing cells remained tumor-free, whereas all 5 mice 
injected with control 231 cells had large tumors (Figure 28 A, B; Table 1). 
 
NPRL2/TUSC4 knockdown transforms normal mammary epithelial cells      
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           Previous reports indicated that HR repair defect sensitizes cancer cells to 
DNA damaging drug (Foray et al., 1999; Deng and Wang 2003) and the poly(ADP-
ribose) polymerase  (PARP) inhibitor (Alli et al, 2009; Powell et al., 2003). Thus, 
NPRL2/TUSC4 deficiency cells with HR repair defect are highly likely to be more 
sensitive to the treatment of PARP inhibitor, which can effectively inhibit the repair 
of single strand DNA break. To confirm this hypothesis, we performed colony 
formation assay in U2OS cell with NPRL2/TUSC4 knockdown after PARP inhibitor 
Olaparib and Rucaparib treatment, as well as control cells. As we expected, both 
drug significantly reduced the colony formation in NPRL2/TUSC4 knockdown cells 
compared the control cells (Figure 29 A, B). Additionally, we examined 
NPRL2/TUSC4 depletion to determine whether it initiates breast tumor 
development in a xenograft mouse model. We injected MCF-10A cells with stable 
knockdown of NPRL2/TUSC4 expression and the control cells into the mammary 
fatpads of female nude mice. Similarly to the procedure described above, we 
closely monitored tumor formation in the mice. Notably, tumors began to form in 3 
of 10 mice injected with NPRL2/TUSC4-knockdown cells after 3 weeks, whereas 
no tumors formed in the control groups (Table 2). These results demonstrated that 
loss of NPRL2/TUSC4 expression alone is sufficient to initiate malignant 
transformation of immortalized nontransformed mammary epithelial cells, which is 
consistent with our hypothesis that NPRL2/TUSC4 functions as a bona fide tumor 
suppressor in breast cancer. 
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NPRL2/TUSC4 also regulate the foci formation of Rad51 
        We also performed Rad51 foci staining followed by IR irradiation. 
NPRL2/TUSC4 knockdown significantly demolished the BRCA1 foci formation after 
irradiation, whereas control small interfering RNA (siRNA) did not affect the 
formation of Rad51 foci. Previous reports has suggested BRCA1 promote the 
recruitment of Rad51 and  Rad51 forms complex with BRCA1 in the HR repair, it's 
highly likely the knockdown of NPRL2/TUSC4 reduced BRCA1 expression and 
further lead in the Rad51 foci formation decrease (Figure 31 A, B). 
 
NPRL2/TUSC4 knockdown delays cell cycle after irradiation 
            We have proven that knockdown of NPRL2/TUSC4 under normal 
conditions, next we sought to investigate if NPRL2/TUSC4 is associated with cell 
cycle arrest under stress conditions.  So, we added hydroxyurea (HU) into medium 
cultured with both control cells and NPRL2/TUSC4 knockdown cells, we observed 
that NPRL2/TUSC4-deficient cells exhibited noticeable slower cell cycle recover 
from G1 arrest compare to control cells and NPRL2/TUSC4 deficient cells with 
reintroduction of NPRL2/TUSC4 plasmid transfected cells. All the samples were 
also treated with Taxol which is widely used in cell biology to cause G2/M phase 
arrest. After 8 hours of Taxol treatment, control cells were already arrested in G2 
while both NPRL2/TUSC4 deficient and NPRL2/TUSC4 transfected cells were still 
blocked in G1, but after 16 hours of treatment, NPRL2/TUSC4 deficient cells were 
shifted into G2 arrest, while both control cells and NPRL2/TUSC4 transfected cells  
were able to break the G2 arrest (Figure 32). 
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       As an alternative way to evaluate the if cells can recover from stress, 
phosphorylated histone 3 is used to indicate the mitosis activity, so we also 
performed p-H3 staining to evaluate if proliferation rate of NPRL2/TUSC4 deficient 
cells were affected. As shown in figures, after 8 hours and 16 hours of Taxol 
treatment followed by HU removal, control cells had 1.28% and 12.8% p-H3 
positive population while NPRL2/TUSC4 deficient cells had only 0.82% and 5.86% 
p-H3 positive population respectively, that was about 50% decrease of mitotic level 
compare to control cells. NPRL2/TUSC4 transfected sample didn’t display high p-
H3 as the control cell, but after 8 hours and 16 hours of Taxol treatment followed 
by HU removal, the p-H3 positive population was 1.54% and 1.5% compare to 
0.025% and 0.040% in NPRL2/TUSC4 deficient cells, similar results supported the 
role of NPRL2/TUSC4 in replication stress recovery were described previously. 
Together, these results suggested NPRL2/TUSC4 plays an important role in 
maintain genomic stability and inhibit the proliferations of breast tumor cells both in 
vitro and in vivo, and this function is dependent on NPRL2/TUSC4’s capacity to 
stabilize tumor suppressor BRCA1 and regulate cell cycle checkpoint, HR repair 
(Figure 33 A, B). 
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Figure 28. NPRL2/TUSC4 plays an important role as a tumor suppressor in 
breast cancer 
A. NPRL2/TUSC4 overexpression in MDA-MB-231cells (stable clones 
NPRL2/TUSC4 #7 and #13) significantly reduced the breast tumor growth in 
nude mice (p<0.05) compared to control 231 cells, the relative tumor size were 
indicated and compared as shown. 
B. Tumor growth percentage of total injected mice by week after the injection of 
the MDA-MB-231 cells as well as two NPRL2/TUSC4 overexpression cell lines 
(#7 and #13). 
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Figure 29.  NPRL2/TUSC4 deficiency sensitized U2OS cells to PARP inhibitor  
A. Colony formation assay indicated that normal U2OS cells are not sensitive to 
PARP inhibitor Olaparib (1μm) but NPRL2/TUSC4-knockdown cells exhibited 
increased sensitivity to Olaparib, the colonies were significantly reduced after the 
treatment (p<0.05); 
B. Colony formation assay indicated that normal U2OS cells are not sensitive to 
PARP inhibitor Rucaparib (1μm) but NPRL2/TUSC4-knockdown cells exhibited 
increased sensitivity to Rucaparib, the colonies were significantly reduced after the 
treatment (p<0.05). 
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Table 1. Tumorigenecity  of MDA-MB231 cells with NPRL2/TUSC4 
overexpression  
5×106 cells from MDA-AB-231 control and two independent NPRL2/TUSC4-
overexpressing MDA-AB-231 cell lines (NPRL2/TUSC4 #7 and NPRL2/TUSC4 
#13) were injected per mouse into mammary tumor sizes were analyzed. 
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Table 2. Tumorigenecity  of MCF10A cells with NPRL2/TUSC4 depletion  
1×107 cells from MCF-10A control and two independent NPRL2/TUSC4-
knockdown MCF-10A cell lines (NPRL2/TUSC4 #1 and NPRL2/TUSC4 #4) were 
injected per mouse into mammary fat pads glands of 6-week-old female nude mice. 
Each cell line was injected in five different mice, and tumor sizes were analyzed. 
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D. 
 
Figure 30. Colony formation assay of NPRL2/TUSC4 overexpression and 
NPRL2/TUSC4 knockdown cells 
A. Colony formation of MDA-MB-231 cells, as well as 2 stable NPRL2/TUSC4 
overexpression 231 cells (#7 and #13) before injection was displayed. B. Western 
Blot confirmed the NPRL2/TUSC4 overexpression in 231 cells, including #7 and 
#13.  C. Colony formation of  MCF-10A cells, as well as 2 stable 10A knockdown 
cell lines (#1 and #4) before injection was displayed. D. Western Blot confirmed the 
NPRL2/TUSC4 knockdown  in 10A cells, including clone #1 and #4. 
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Figure 31. NPRL2/TUSC4 knockdown reduced Rad51 protein foci after UV  
NPRL2/TUSC4 knockdown reduced Rad51 foci formation after UV, while control 
cells (NT) didn’t have such effect. BRCA1 indicated the efficiency of irradiation. 
 
 
 
 
 
- 81 - 
 
 
 
 
Figure 32. NPRL2/TUSC4 depletion slowed down the cell cycle progression 
under stress conditions 
Control, NPRL2/TUSC4 knockdown and  NPRL2/TUSC4 knockdown/reintroduction 
cells were treated with HU for 24 hours, then HU were removed and Taxol were 
added to arrest cells in G2 phase, 0 h, 8 h, 16 h after Taxol treatment were 
collected for cell cycle analysis 
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Figure 33. NPRL2/TUSC4 depletion is associated with reduced proliferation 
rate 
A. NPRL2/TUSC4 depleted cells showed significantly reduced p-H3 staining 
compare to control cells after Taxol treatment in 8 hours and 16 hours; 
B. Reintroduction of NPRL2/TUSC4 and CHK1 in NPRL2/TUSC4 depleted cells 
rescued p-H3 staining compare to NPRL2/TUSC4 depleted cells alone. All cells 
were treated with HU for 24 hours and Taxol for 8 or 16 hours. 
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Chapter 5 
DISCUSSION 
            DNA damage response is critical to maintain genomic integrity and it 
safeguards the fidelity of genetic information to pass to the next generation of cells. 
The deficiency of DNA damage response especially in the early stage increased 
the incidence of cancer lesions. As one of the most important protein in DNA 
damage response, BRCA1 mediates the error-free homologous recombination 
repair and suppress the occurrence of early cancer lesions. Here we provided 
evidence that tumor suppressor protein NPRL2/TUSC4 can stabilize the 
expression levels of BRCA1 by preventing BRCA1's E3 ligase HERC2 from binding 
it. Interestingly, inactivation of NPRL2/TUSC4 has also been shown to associate 
with poor 5-year clinical survival rates in breast cancer patients, indicating 
NPRL2/TUSC4 plays a role in inhibiting tumor growth and maintaining genome 
integrity against the multiple types of stress.  
           BRCA1's recruitment to damage sites is considered one of the critical 
events in HR repair. Inactivation of NPRL2/TUSC4 abolished the DNA damage foci 
of BRCA1 under both IR and UV treatments, suggested the regulation BRCA1's 
stability in DNA damage response may not only go through the process followed by 
the CHK2 phosphorylation, due to the lack of kinase activity of NPRL2/TUSC4. In 
fact, a previous report described that NPRL2/TUSC4 inhibits AKT pathway by 
physically interacting with the upstream PDK1 protein, and it can block the 
phosphorylation sites on PDK1 and prevents co-activator Src from binding. Thus, 
it's not surprising that NPRL2/TUSC4's binding domain is responsible for multiple 
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proteins' interaction and functions as tumor suppressor. Indeed, NPRL2/TUSC4 
does bind to BRCA1's E3 ligase HERC2 but not with BRCA1 itself.  
          Our initial observation that NPRL2/TUSC4 can form damage foci after UV 
and IR suggested that NPRL2/TUSC4's potential function in nuclear. This result 
was confirmed by nuclear fractionation experiments showing that NPRL2/TUSC4 is 
diversely expressed from cytoplasm to nuclear. Although it's not clear whether 
NPRL2/TUSC4 co-localizes with BRCA1 after irradiation, we noticed that after 
NPRL2/TUSC4 was knocked down, BRCA1 foci was significantly reduced. This 
leads to two possibilities; either BRCA1's stability was impaired thus foci couldn't 
be formed or the BRCA1's recruitment to damaged sites was blocked. Considering 
BRCA1's important role in homologous recombination repair, we suspected that if 
BRCA1's expression level is reduced, the HR repair efficiency would also get 
affected. So, we used previously established U2OS cell systems to evaluate the 
HR repair efficiency by the levels of released GFP. The graphs clearly show that 
knockdown of NPRL2/TUSC4 has similar effects compared to BRCA1 knockdown 
samples, which served as positive control. This results was consistent with our 
hypothesis that inactivation of NPRL2/TUSC4 leads to the reduced expression 
levels of BRCA1. More interestingly, after the analysis of Western blots, we also 
identified that BRCA1's expression level was significantly reduced in the lane of 
NPRL2/TUSC4 knockdown sample, indicating the NPRL2/TUSC4 inactivation 
leads to the decreased stability of BRCA1 protein itself. These data support the 
idea that reduced BRCA1 damage-induced foci is due to reduced BRCA1 stability. 
However, we still can't rule out the possibility that NPRL2/TUSC4 inactivation also 
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impairs the cell’s capacity to recruit BRCA1 to the foci sites. Furthermore, to 
confirm that the defective HR repair efficiency was not caused by transfection 
efficiency or inaccurate efficiency from I-SceI, we reintroduced BRCA1 plasmids 
into the NPRL2/TUSC4-knockdown cells, and as expected, we observed a 
significant increase in HR repair efficiency compare to that in NPRL2/TUSC4-
knockdown-only cells. The introduction of BRCA1 expression caused partial 
restoration of HR repair efficiency, the main reason is that NPRL2/TUSC4 also 
interacts with other DNA damage response and repair proteins involved in HR 
repair (data not shown).  
        For a better understanding of the relationship between NPRL2/TUSC4 and 
BRCA1, we first conducted microarray analysis by using the NPRL2/TUSC4 stable 
U2OS cell lines with the appropriate controls. We then isolated the significantly 
different genes with both up- and down-regulation and input into Ingenuity Pathway 
Analysis (IPA) system for pathway enrichment analysis. The results indicated 
NPRL2/TUSC4 knockdown leads to the critical pathway changes including cancer, 
cell cycle, cell death, etc. This is consistent with the previous studies that 
NPRL2/TUSC4 has been widely accepted as a tumor suppressor gene. Top 
molecular pathways also indicated NPRL2/TUSC4 knockdown cells is associated 
with role of BRCA1 in DNA damage response, which further supported our 
statement that NPRL2/TUSC4 knockdown is negatively associated BRCA1's 
function. 
         We previously established HR repair-deficiency gene signatures and 
identified 230 genes that predict HR repair deficiency across tumor types. BRCA1 
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deficiency had been utilized as one of the phenotypes to generate the signature. 
We surprisingly identified similar HRD gene signature patterns in NPRL2/TUSC4- 
and BRCA1-deficient cells, suggesting an association between these two proteins 
and shedding light for the exploration of regulation networks for NPRL2/TUSC4 
and BRCA1. To further validate this hypothesis, we also performed RPPA with 
BRCA1 and NPRL2/TUSC4 deficient cells as well as control cells, at the protein 
level, NPRL2/TUSC4 and BRCA1 knockdown exhibited similar protein expression 
patterns in the clusters, indicating similar protein and pathway changes were 
observed and this result is highly consistent with the microarray analysis at mRNA 
level.  Multiple research groups published that BRCA1-deficicency is correlated 
with high sensitivity of tumor cells and animal models to PARP inhibitor. The 
underlying mechanism is that inhibition of PARP1 will accumulate unrepaired single 
strand break and ultimately leads to double strand break. Our data also showed the 
TSUC4 deficient cells are more sensitive to the treatment of multiple PARP 
inhibitors, which is consistent with the rationales of our work. It also suggested the 
potential clinical usage of PARP inhibitors to treat NPRL2/TUSC4-defieicent breast 
cancer. 
        To determine whether the regulation of BRCA1 by NPRL2/TUSC4 is caused 
by the altered cell-cycle distribution because BRCA1 expression is known to be 
cell-cycle regulated, we first performed cell cycle analysis and found no significant 
difference between the normal U2OS cells and NPRL2/TUSC4 stable knockdown 
cells. This ruled out the possibility the reduced BRCA1 expression level is due to 
the different stages of cell cycle. To test whether BRCA1 is regulated by 
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NPRL2/TUSC4 at the mRNA level, RT-PCR was performed. We observed that 
BRCA1 mRNA levels had no significant differences between control cells and two 
NPRL2/TUSC4 deficient cells. This result is also consistent with the previous 
microarray analysis, which showed no changes at the BRCA1 mRNA level, even 
clear molecular pathway changes were identified.  
   Another possibility could be that NPRL2/TUSC4 regulates BRCA1's 
stability at the protein level. To determine if this hypothesis is true, we treated 
control and NPRL2/TUSC4-knockdown U2OS cells with CHX, for the purpose of 
blocking protein synthesis, and proteasome inhibitor MG132. Surprisingly, we 
found that NPRL2/TUSC4 knockdown reduced the half-life of BRCA1 from about 
20 h to less than 6 h. MG132-based treatment restored BRCA1 expression in cells 
with NPRL2/TUSC4 knockdown but such phenotype was not observed in control 
cells. These two results combined together suggested that NPRL2/TUSC4 plays an 
essential role in stabilizing BRCA1 at the protein level and NPRL2/TUSC4 
regulates BRCA1 protein stability via the proteasome-dependent pathway. Multiple 
groups have reported HERC2 serves as the E3 ligase of BRCA1. To determine 
whether NPRL2/TUSC4 regulates BRCA1 stability via HERC2, we performed 
ubiquitination assay by transfecting (HA)-tagged ubiquitin plasmids into cells with 
or without NPRL2/TUSC4 knockdown, followed by immunoprecipitation with control 
IgG or an anti-BRCA1 antibody. After treatment with MG132, Western blotting for 
HA-tagged ubiquitin showed that NPRL2/TUSC4-knockdown cells underwent 
heavy ubiquitination, whereas control cells exhibited only a light polyubiquitination 
ladder indicating that knockdown of NPRL2/TUSC4 expression caused a robust 
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increase in BRCA1 protein polyubiquitination.  We also confirmed that depletion the 
expression of HERC2 led to increased expression of BRCA1 regardless of the 
presence of NPRL2/TUSC4. These data further suggested the role of 
NPRL2/TUSC4 in regulation of BRCA1 stability via ubiqutination pathway via 
HERC2.  
Thus, the next question to be answered was how NPRL2/TUSC4 affects the 
ubiquitination of BRCA1 via HERC2. By performing immunoprecipitation, we found 
that NPRL2/TUSC4 physically interacts with HERC2 but not with BRCA1, which 
strongly suggested that NPRL2/TUSC4 regulates BRCA1 stability via interaction 
with HERC2. Considering the previously reported binding functions of 
NPRL2/TUSC4, we suspected that NPRL2/TUSC4 may prevent physical 
interaction between BRCA1 and HERC2. The binding between these two proteins 
has been previously described, so we performed further immunoprecipitation to 
determine whether overexpression of NPRL2/TUSC4 weakens this binding. 
Intriguingly, overexpression of NPRL2/TUSC4 interrupted the binding between 
HERC2 and BRCA1, indicating that NPRL2/TUSC4 may regulate BRCA1 stability 
by preventing physical interaction between BRCA1 and HERC2. 
In the present study, we demonstrated for the first time that expression of 
NPRL2/TUSC4 can positively regulate the stability of BRCA1 by preventing 
physical interaction between BRCA1 and its identified E3 ligase HERC2, which in 
turn protects BRCA1 from ubiquitination and degradation. Because NPRL2/TUSC4 
knockdown is negatively correlated with BRCA1 protein expression and 
considering the previously reported protein-binding and -blocking capacity of 
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NPRL2/TUSC4 between PDK1 and its co-activator Src, we suspected that 
NPRL2/TUSC4 plays a similar role in disrupting the interaction between BRCA1 
and HERC2. Indeed, we found that NPRL2/TUSC4 physically interacts with 
BRCA1’s E3 ligase HERC2 but not with BRCA1 itself. Overexpression of 
NPRL2/TUSC4 markedly weakened their interaction in immunoprecipitation 
experiments. This observation explained how NPRL2/TUSC4 overexpression can 
protect BRCA1 from degradation and greatly reduce the proliferation of breast 
cancer. Thus, the regulatory mechanisms of NPRL2/TUSC4 function in blocking 
the AKT pathway and stabilizing BRCA1 protein expression may be similar. 
NPRL2/TUSC4 does not have phosphorylation or E3 ligase activity according to 
functional domain analysis, so we speculated that its potential functions in the DNA 
damage response network and as a tumor suppressor are common mechanisms 
by the physical interaction, stabilizing or preventing activation of target proteins. 
Regardless of the effect of HERC2 on BRCA1, our data has demonstrated 
that  NPRL2/TUSC4 inactivation significantly impaired the stability of BRCA1, and 
in turn negatively regulate the efficiency of HR repair and cells' capacity to 
response to PRAP inhibitor. We demonstrated further that the reduced stability of 
BRCA1 is owing to its E3 ligase HERC2 binding, and NPRL2/TUSC4 can 
physically interact with HERC2 and weaken the binding between BRCA1 and 
HERC2. When NPRL2/TUSC4 is inactivated, HERC2 is able to reform the binding 
complex with BRCA1 and thus decrease BRCA1's expression via protein 
degradation pathway. Our data strongly supported our hypothesis that 
NPRL2/TUSC4 regulates BRCA1's stability.  
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            BRCA1 expression level was reported to be negatively regulated by 
apoptosis pathway under the condition of UV. More specifically, BRCA1 is cleaved  
by caspase-3 after UV treatment, while mutated BRCA1 with non-cleavable 
capacity can negatively regulate cell death and block GADD5/JNK signaling (Zhan 
et al., 2002).  Although BRCA1 plays an important role in DNA damage response 
and repair, the mechanism of when BRCA1 participates into the DNA double 
strand break response is still largely unknown. Thus, to understand the 
physiological condition of when BRCA1 is regulated will promote our understanding 
when and why the regulation between NPRL2/TUSC4 and BRCA1 take place. In 
fact, our data (not shown) also indicated that NPRL2/TUSC4 knockdown altered 
the cell cycle distributions of U2OS cells compare to ATM or ATR knockdown, after 
IR treatments. Considering BRCA1 is cell cycle dependent, this result suggested 
the regulation of BRCA1 by NPRL2/TUSC4 may not only happen under normal 
conditions, but also play roles under the conditions of IR. However, further 
research need to be performed to confirm this hypothesis. 
         Upon DNA damage, BRCA1 was previously reported to aggregate and co-
localize with γ-H2AX to the nuclear foci (Paull et al., 2000). Multiple factors can 
affect BRCA1's foci formation including UBC13/RNF8 ligase in ubiquitination 
pathway (Wang and Elledge, 2007). In our current study, although the knockdown 
of NPRL2/TUSC4 reduced the stability of BRCA1, but whether the reduced BRCA1 
foci formation was owing to the reduced BRCA1 expression is still unknown. 
Considering the fact that NPRL2/TUSC4 regulates BRCA1's stability via the 
ubiquitination pathway, it's also likely that NPRL2/TUSC4 also involves the 
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BRCA1's recruitment to the foci.  This hypothesis can be tested by checking if 
NPRL2/TUSC4 co-localize with BRCA1 after irradiation. 
         Another function of NPRL2/TUSC4 was reported in 2013 (Bar-Peled, 2013), 
explaining that NPRL2/TUSC4 forms complex with NPRL3 and DEPDC5 to 
negatively regulate mTORC1 pathway. Inactivation of this complex will lead 
hyperactive cell growth, due to the insensitivity to amino acid deprivation, and 
hypersensitive to mTORC1 target drug rapamycin. Because Gag guanosine 
triphosphatases (GTPases) involves in the translocation of mTORC1 to lysosomal 
surface, and the complex mentioned above suppress the GTPases activity, this 
result suggested that NPRL2/TUSC4’s potential function in promoting or 
suppressing the protein trafficking, and might shuttle proteins among different 
cellular apparatuses. In fact, nuclear transport of BCRA1from cytoplasm to the 
nucleus by NLS receptor mediated system has been previously described (Chen et 
al, 1996). Therefore, the regulation location between NPRL2/TUSC4 and BRCA1 
needs to be further investigated. Additionally, the difference between normal 
conditions and under irradiation will also need to be compared. In other words, 
upon the DNA damage response, will BRCA1 be shuttled from cytoplasm to 
nucleus, and whether NPRL2/TUSC4 stabilizes BRCA1 in nucleus? If this is true, 
the recruitment of NPRL2/TUSC4 to DNA damage foci will occur with BRCA1’s 
transport simultaneously, even NPRL2/TUSC4 doesn’t physically interact with 
BRCA1. In this case, future work still need to be done to identify the mechanism 
behind NPRL2/TUSC4 also positively regulates BRCA1’s stability at normal 
physical conditions, is there any feedback loop involves in this negative regulation 
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of BRCA1 expression to maintain the minimal BRCA1 expression level 
(Baldassarre G et al, 2003; Mueller CR and Roskelley CD, 2003). 
        Other than HR repair, BCRA1 was also reported to associate with KU80 
during NHEJ repair to maintain the fidelity end-joining and maintain the repair 
efficiency (Jiang et al, 2013). However, the regulation only happens in certain types 
of NHEJ (in-vivo precise NHEJ), thus, even NPRL2/TUSC4 might play roles in 
regulating NHEJ repair, such functions are most likely to limited into the framework 
of BRCA1 stability based on our current understanding.  However, further research 
can be performed to identify if NPRL2/TUSC4 affect the activities of critical NHEJ 
repair effectors such as KU70-KU80 dimers and 53BP1. 
 
 
Clinical relevance of NPRL2/TUSC4 regulation of BRCA1 
 We have identified NPRL2/TUSC4 functions as tumor suppressor gene in 
breast cancer, possibly through positively regulating BRCA1. Next, we postulated 
that overexpression of NPRL2/TUSC4 also suppresses breast tumor proliferation in 
vitro and in vivo. To validate this, we compared the proliferation rate of the breast 
cancer cell line MDA-MB-231 with or without NPRL2/TUSC4 overexpression. 
Colony formation assays indicated markedly reduced proliferation of the 
NPRL2/TUSC4-overexpressing cells (Figure 30A). Because NPRL2/TUSC4 
effectively inhibits breast cancer cell growth in vitro, we further examined the effect 
of NPRL2/TUSC4 overexpression in a xenograft mouse model of breast cancer. 
We injected female mice with control or NPRL2/TUSC4-overexpressing MDA-MB-
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231cells into the mammary fatpads. We then monitored and measured tumor 
growth weekly. By week 6 after injection, 5 of 10 mice injected with 
NPRL2/TUSC4-overexpressing cells remained tumor-free, whereas all 5 mice 
injected with control 231 cells had large tumors (Figure 28 A, B; Table 1). 
Previous reports indicated that HR repair defect sensitizes cancer cells to 
DNA damaging drug (Foray et al 1999; Deng and Wang 2003) and the poly(ADP-
ribose) polymerase (PARP) inhibitor (Alli et al., 2009; Powell and Kachnic, 2003). 
Thus, NPRL2/TUSC4 deficiency cells with HR repair defect are highly likely to be 
more sensitive to the treatment of PARP inhibitor, which can effectively inhibit the 
repair of single strand DNA break. To confirm this hypothesis, we performed colony 
formation assay in U2OS cell with NPRL2/TUSC4 knockdown after PARP inhibitor 
Olaparib and Rucaparib treatment, as well as control cells. As we expected, both 
drug significantly reduced the colony formation in NPRL2/TUSC4 knockdown cells 
compared the control cells (Figure 29 A,B). Additionally, we examined 
NPRL2/TUSC4 depletion to determine whether it initiates breast tumor 
development in a xenograft mouse model. We injected MCF-10A cells with stable 
knockdown of NPRL2/TUSC4 expression and the control cells into the mammary 
fatpads of female nude mice. Similar to the procedure described above, we closely 
monitored tumor formation in the mice. Notably, tumors began to form in 3 of 10 
mice injected with NPRL2/TUSC4-knockdown cells after 3 weeks, whereas no 
tumors formed in the control groups (Table 2). These results demonstrated that 
loss of NPRL2/TUSC4 expression alone is sufficient to initiate malignant 
transformation of immortalized nontransformed mammary epithelial cells, which is 
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consistent with our hypothesis that NPRL2/TUSC4 functions as a bona fide tumor 
suppressor in breast cancer. 
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Chapter 6 
FUTURE WORK 
Further explore the interaction between NPRL2/TUSC4 and HERC2 
          We have successfully identified that NPRL2/TUSC4 physically interacts with 
E3 ligase HERC2 but not BRCA1, thus blocking the binding between HERC2 and 
BRCA1, in turn stabilizing BRCA1's expression and maintaining its functions in HR 
repair and other DNA damage responses. Previous report indicated 
NPRL2/TUSC4's N-terminal 133 amino acid residues are responsible for the 
binding of NPRL2/TUSC4 to PDK1's phosphorylation sites (Kurata et al., 2008). 
Also, HERC2's C-terminal HECT domain is responsible for the binding of BRCA1's 
N-terminal degron domain (Wu et al, 2010). The unanswered question is whether 
NPRL2/TUSC4's N-terminal domain is also responsible for the binding of HERC2, 
and if so, is HERC2's C-terminal domain involved in the binding. We have 
generated deletion mutations of NPRL2/TUSC4-FLAG stable clones to test this 
hypothesis. If the results show that NPRL2/TUSC4's N-terminus physically interact 
with HERC2's c-terminus, it will not only confirm the functions of both 
NPRL2/TUSC4 and HERC2 's binding domain, but it will also provide clinical 
insights to target binding domains of HERC2 to treat BRCA1down-regulation 
patients in multiple types of cancers (Moskwa et al, 2010; Deutsch et al.,2003; 
Beger et al., 2004).  Furthermore, it has been also shown BARD1 protects BRCA1 
from HERC2-mediated ubiquitination and HERC2 degrades BRCA1 regardless of 
the existence of BARD1 (Wu et al., 2010). as an extensively studies BRCA1-Ring 
domain binding protein, if NPRL2/TUSC4 knockdown affect BARD1's binding with 
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BRCA1, if so, does this disassociation allow BRCA1's RING domain becomes 
more accessible for HERC2’s targeting? An alternative model could be 
NPRL2/TUSC4 binds HERC2 and BARD1 (instead of BRCA1) to realize its 
function in mediating BRCA1's stability.  Together these experiments could provide 
evidence to support our current model or to help establish revised model of 
NPRL2/TUSC4's function in BRCA1 and HERC2 interaction (Figure 23, 24). 
 
Determine the function of NPRL2/TUSC4 in replication stress response 
          Besides the data shown in this dissertation, we have also discovered the 
association of NPRL2/TUSC4 in replication stress response. NPRL2/TUSC4 
exhibited extensive binding capacity to proteins other than PDK1 and HERC2, as 
mentioned previously. Other major DNA damage response kinase such as ATM 
and ATR also physically interact with NPRL2/TSUC4. This would explain our 
observation in the HR repair assay that double knockdown of TSUC4 and BRCA1 
further reduced the reporter protein GFP's level, and overexpression of BRCA1 in 
the cells with NPRL2/TUSC4 knockdown didn't completely restore the HR repair 
efficiency. If BRCA1 is not the only downstream targets of NPRL2/TUSC4 
inactivation, the phenomenon we observed matched the hypothesis that 
NPRL2/TUSC4 play a more intensive role in DNA damage response network. 
Although NPRL2/TUSC4 knockdown cells shows no significant difference of cell 
cycles distribution compare to control, after both cells were treated with 
Hydroxyurea (HU), NPRL2/TUSC4-deficient cells exhibited extended G1 arrest 
while controls cells were able to escape from G1 arrest. This data suggested 
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NPRL2/TUSC4's function in mediating cell cycle checkpoints, which is consistent 
with our previous IPA analysis, which indicated that NPRL2/TUSC4 knockdown 
globally changed the gene expression profiles of cell cycle checkpoint regulation 
and DNA damage responses. The mechanisms under this regulation needs to be 
explored to test if these bindings are also regulated by the ubiquitination pathway. 
Based on the recent findings that NPRL2/TUSC4 mRNA levels are significantly 
reduced with the progression of cancer development, and low NPRL2/TUSC4 level 
correlates with multiple drugs' resistance so it is worth taking the possibility into 
consideration in which decreased NPRL2/TUSC4 expression levels are associated 
with the stability or functions of these major DNA damage response kinase. 
Understanding of the mechanism whereby NPRL2/TUSC4 negatively regulates 
these kinases is significant because of the effect it has on replication stress 
response and potential application in clinical drug design or selection. Most likely, 
these regulation will process through the binding or blocking due to the lack of 
functional domains of NPRL2/TUSC4 such as phosphoryation, so the direct 
regulation of NPRL2/TUSC4 to these kinase is not likely. But considering, the 
conserved SQ/TQ motif in NPRL2/TUSC4 sequences cross the species, it's highly 
possible NPRL2/TUSC4 can also serve as the binding substrates of ATM/ATR 
protein, and regulate their activities.      
 
Further demonstrate NPRL2/TUSC4-deficient cells' drug sensitivity 
          We have identified the increased sensitivity of U2OS cells with 
NPRL2/TUSC4-deficiency, largely due to decreased BRCA1 stability and impaired 
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HR repair capacity by the cells. The signatures involves in HR repair deficiency has 
been established by our previous work (Peng et al., 2014). Although 
NPRL2/TUSC4 KD can also clearly form a cluster pattern based on the 230 
identified gene signatures, it will be interesting to evaluate the changes in more 
details. For example, HR repair proteins other than BRCA1 could also be involved 
after NPRL2/TUSC4's expression is reduced. It's logical that these gene changes 
in NPRL2/TUSC4 deficient cells overlaps BRCA1 deficiency (and PTEN deficiency) 
gene signatures which the signature established from, it actually narrowed down 
the numbers of genes potentially involves in the pathways followed by 
NPRL2/TUSC4 inactivation. Additionally, NPRL2/TUSC4's low expression has also 
been identified as the cause of CPT resistance in lung cancer. The proposed 
mechanism is that NPRL2/TUSC4 deficiency failed to stabilize the DNA damage 
response signaling cascades (Jayachandran et al., 2010). It's still unclear what 
other proteins associated with drug responses after NPRL2/TUSC4's inactivation 
and it would be interesting to map out the pathways affected by NPRL2/TUSC4's 
deficiency, and to determine if BRCA1 is the only readout which affected the 
sensitivity of drug treatment such as PARP inhibitors and DNA damaging reagents. 
Annexin V staining can also be conducted to investigate if NPRL2/TUSC4 
knockdown leads to the increase of apoptosis cell populations before and after 
treatment with different drugs. We propose that depending on the drugs' 
mechanism and target, the results will not provide same effect of TSUC4 deficiency 
cells, it also needs to take the cell or cancer types into consideration.    
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Further investigate NPRL2/TUSC4's role as a tumor suppressor  
            We and others provide evidence that both NPRL2/TUSC4 overexpression 
in vitro and in vivo inhibited breast cancer cell proliferation and tumor development. 
The same effect of NPRL2/TUSC4 was identified in non-small cell lung cancer (Li 
et al., 2004). Moreover, we showed for the first time that depletion of 
NPRL2/TUSC4 in non-transformed 10A cell lines promoted the genomic instability 
and lead to the occurrence of early breast cancer lesions in nude mice models. To 
further confirm this hypothesis, additional experiments are necessary to include 
into the future work. For example, comet assay can be done to determine the 
genomic instability after NPRL2/TUSC4 knockdown and invasion assay can be 
done to explore if NPRL2/TUSC4 deficiency increases cell's malignancy and 
mobility.  
        In our in vivo experiments, we injected MDA-MB-231 cells with 
NPRL2/TUSC4-flag overexpression into nude mice and observed much slower 
tumor growth rates compared to normal MDA-MB-231 cells. MDA-MB-231 cells are 
categorized as basal breast cancer cell lines, which share common characteristics 
as triple negative breast cancer types (Badev et al., 2011). We identified that 
NPRL2/TUSC4 knockdown cells exhibit a more basal-like gene expression profiles 
than luminal. This indicates that NPRL2/TUSC4 can serve as a biomarker to treat 
basal-like or triple negative breast cancer, or the marker to indicate therapy 
efficiency.  Drug screening will also be extremely useful to distinguish if 
NPRL2/TUSC4 can be used as marker for that purpose. Together, these 
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experiments will lead us to a better understanding of the roles of NPRL2/TUSC4 as 
tumor suppressor.  
            Finally, since NPRL2/TUSC4 expression levels vary depending on organs 
and tissues, it would be interesting to investigate whether this protein functions only 
in maintaining genome stability, and whether its function across various cancers is 
tissue-specific. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
- 102 - 
 
REFERENCES 
 
Alli E, Sharma V.B, Sunderesakumar P, and Ford J.M. (2009). Defective Repair of 
Oxidative DNA Damage in Triple-Negative Breast Cancer Confers Sensitivity to 
Inhibition of Poly(ADP-Ribose) Polymerase. Cancer Research 69, 3589-3596. 
Badve S, Dabbs D.J, Schnitt S.J, Baehner F.L, Decker T, Eusebi V, Fox S.B, 
Ichihara S, Jacquemier J, Lakhani S.R, Palacios J, Rakha E.A, Richardson A.L, 
Schmitt F.C, Tan P.H, Tse G.M, Weigelt B, Ellis I.O, and Reis-Filho J.S. (2011). 
Basal-like and triple-negative breast cancers: a critical review with an emphasis on 
the implications for pathologists and oncologists. Modern Pathology 24, 157-167. 
Bartek J and Lukas J. (2003). Chk1 and Chk2 kinases in checkpoint control and 
cancer.  Cancer Cell 3, 421-429. 
Bar-Peled L, Chantranupong L, Cherniack AD, Chen WW, Ottina KA, Grabiner BC, 
Spear ED, Carter SL, Meyerson M and Sabatini DM. (2013) A tumor suppressor 
complex with GAP activity for the Rag GTPases that signal amino acid sufficiency 
to mTORC1. Science 340, 1100-1106. 
Baldassarre G, Battista S, Belletti B, Thakur S, Pentimalli F, Trapasso F, Fedele M, 
Pierantoni G, Croce CM and Fusco A. (2003). Negative regulation of BRCA1 gene 
expression by HMGA1 proteins accounts for the reduced BRCA1 protein levels in 
sporadic breast carcinoma. Molecular and cellular biology 23(7), 2225-2238. 
Beger C, Ramadani M, Meyer S, Leder G, Kruger M, Welte K, Gansauge F, and 
Beger H.G. (2004). Down-Regulation of BRCA1 in Chronic Pancreatitis and 
Sporadic  Pancreatic Adenocarcinoma. Clinical Cancer Research 10, 3780-3787. 
 
 
- 103 - 
 
Bekker-Jensen S, Danielsen J.R, Fugger K, Gromova I, Nerstedt A, Lukas C, 
Bartek J, Lukas J and Mailland N. (2009). HERC2 coordinates ubiquitin-dependent 
assembly of DNA repair factors on damaged chromosomes. Nature Cell Biology 
12, 80-86. 
Ciccia A and Elledge S.J. (2010). The DNA damage response: making it safe to 
play with knives. Molecular Cell 40, 179-204. 
Cortez D, Wang Y, Qin J, Elledge S.J (1999). Requirement of ATM-dependent  
phosphorylation  of BRCA1 in the DNA damage response to double-strand breaks. 
Science 286, 1162-1166. 
Couch F.J, Deshano M.L, Blackwood A, calzone K, Stopfer J, Campeau L, 
Ganguly A, Rebbeck T, and Weber B.L. (1997).  BRCA1 mutations in women 
attending clinics that evaluate the risk of breast cancer. The New England Journal 
of Medicine 336, 1409-1415. 
Deng CX, Wang RH. (2003). Roles of BRCA1 in DNA damage repair: a link 
between development and cancer. Hum. Mol. Genet 12, 113-123. 
Deutsch E, Jarrousse S, Buet D, Dugary A, Bonnet ML, Vozenni-Brotons MC, 
Guilhot F, Turhan A.G, Feunteun J and Bourhis J. (2003). Down-regulation of 
BRCA1 in BCR-ABL-expressing hematopoietic cells. Blood 101, 4583-4588. 
Foray N, Randrianarison V, Marot D, Perricaudet M, Lenoir G, Feunteun J. (1999) 
γ-Rays-induced death of human cells carrying mutations of BRCA1 and BRCA2. 
Oncogene 18, 7334-7342. 
 
 
- 104 - 
 
Gilmore P.E, Quinn J.E, Mullan P.B, Andrews H.N, McCabe N, Carty M, Kennedy 
R.D, and Harkin D.P. (2003). Role played by BRCA1 in regulating the cellular 
response to stress. Cellular Stress Responses and Cancer 31, 257-262. 
Glickman M.H, and Ciechanover A. (2002). The ubiquitin-proteasome proteolytic 
Pathway: destruction for the sake of construction. Physical Research 82, 373-428. 
Hanahan D and Weinberg R.A. (2000). The hallmarks of cancer. Cell 100,57-70. 
Hanahan D and Weinberg R.A. (2011). Hallmarks of cancer: the next generation. 
Cell 144,646-674. 
Jayachandran G, Ueda K, Wang B, Roth J.A, and Ji L. (2010). NPRL2 Sensitizes 
Human Non-Small Cell Lung Cancer (NSCLC) Cells to Cisplatin Treatment by 
Regulating Key Components in the DNA Repair Pathway. PLoS One 5(8), e11994. 
Ji L, Nishizaki M, Gao B, Burbee D, Kondo M, Kamibayashi C, Xu K, Yen N, 
Atkinson E.N, Fang B, Lerman M.I, Roth J.A and Minna J.D. (2002). Expression of 
several genes in the human chromosome 3p21.3 homozygous deletion region by 
an adenovirus vector results in tumor suppressor activities in vitro and in vivo. 
Cancer Research, 62, 2715-2720. 
Jiang G, Plo I, Wang T, Rahman M, Cho JH, Yang E, Lopez BS and Xia F. (2013). 
BRCA1-Ku80 protein interaction enhances end-joining fidelity of chromosomal 
double-strand breaks in the G1 phase of the cell cycle. J. Bio. Chem 288, 8966-
8976. 
Jin Y, Xu X.L, Yang MC.W, Wei F, Ayi TC, Bowcock A.M, and Bear R. (1997). Cell 
cycle-dependent colocalization of BARD1 and BRCA1 proteins in discrete nuclear 
domains. Proc. Natl. Acad. Sci. USA 94, 12075-12080. 
 
 
- 105 - 
 
Karran P. (2000). DNA double strand break repair in mammalian cells. Current 
Opinion in Genetics & Development 10, 144-150. 
Kennedy R.D, Quinn J.E, Mullan P.B, Johnson P.G, and Harkin D.P. (2004). The 
Role of BRCA1 in the Cellular Response to Chemotherapy.  Journal of the National 
Cancer Institute 96, 1659-1668. 
King MC, Marks J.H, Mandell J.B, and The New York Breast Cancer Study Group. 
Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. 
(2003). Science 302, 643-646. 
Kurata A, Katayama R, Watanabe T, Tsuruo T, and Fujita N. (2008). 
TUSC4/NPRL2, a novel PDK1-interacting protein, inhibits PDK1 tyrosine 
phosphorylation and its downstream signaling. Cancer Science 99, 1827-1834. 
Lee JS, Collins K.M, Brown A.L, Lee CH and Chung J.H. (2000). hCds1-mediated 
phosphorylation of BRCA1 regulates the DNA damage response. Science 404, 
201-204. 
Lehman A.L, Nakatsu Y, Ching A, Bronson R.T, Oakey R.J, Keiper-Hrynko N, 
Finger J.N, Durham -Pierre D, Horton D.B, Newton J.M, Lyon M.F, Brilliant M.H. 
(1998). A very large protein with diverse functional motifs is deficient in rjs (runty, 
jerky, sterile) mice. Proc. Natl. Acad. Sci. USA 95, 9436-9441. 
Lerman M.I and Minna J.D. (2000). The 630-kb lung cancer homozygous deletion 
region on human chromosome 3p21.3: identification and evaluation of the resident 
candidate tumor suppressor genes. Cancer Research 60, 6116-6133. 
Levitt N.C and Hickson I.D. (2002). Caretaker tumour suppressor genes that 
defend genome integrity. Trends in Molecular Medicine 8, 179-186. 
 
 
- 106 - 
 
Li J, Wang F, Haraldson K, Protopopov A, Duh FM, Geil L, Kuzmin I, Minna J.D, 
Stanbridge E, Braga E, Kashuba V.I, Klein G, Lerman M.I, and Zabarovsky E.R. 
(2004). Functional characterization of the candidate tumor suppressor gene 
NPRL2/G21 located in 3p21.3C. Cancer Research 64, 6438-6443. 
Lieber MR, Ma Y, Pannicke U, Schwarz K. (2003) Mechanism and regulation of 
human non-homologous DNA end-joining. Nature Review Molecular Cell Biology 4, 
712-720. 
Lord C.J and Ashworth A. (2012). The DNA damage response and cancer therapy.  
Nature 481, 287-294. 
Lu Y, Li J, Cheng D, Parameswaran B, Zhang S, Jiang Z, Yew P.R, Peng J, Ye Q 
and Hu Y. (2012). The F-box protein FBXO44 mediates BRCA1 ubiquitination and 
degradation. The Journal of Biological Chemistry 287, 410014-41022. 
Lu J and Matuntis M. (2013). A mediator methylation mystery: JMJD1C 
demethylates MDC1 to regulate DNA repair. Nature Structural and Molecular 
Biology 20, 1346-1348. 
Lutzmann M, Greg C, Traver S, Ganier O, Maya-Mendoza A, Ranisavljevic N, 
Bernex F, Nishiyama A, Montel N, Gavois E, Forichon L, Massy B, and Mechali M. 
(2012). MCM8-and MCM9-deficient mice reveal gametogenesis defects and 
genome instability due to Impaired homologous recombination. Molecular Cell 47, 
523-534. 
Medema R.H and Macurek L. (2012). Checkpoint control and cancer. Oncogene 
31, 2601-2613. 
 
 
- 107 - 
 
Moskwa P, Buffa F.M, Pan Y, Panchakshari R, Gottipati P, Muschel R.J, Beech J, 
Kulshrestha R, Abdelmohsen K, Weinstock D.M, Gorpspe M, Harris A.L, Helleday 
T and Chowdhury D. (2010). miR-182-mediated downregulation of BRCA1 impacts 
DNA repair and sensitivity to PARP inhibitors. Molecular Cell 41, 210-220. 
Moynahan M.E, Cui T.Y and Jasin M. (2001). Homology-directed DNA repair, 
mitomycin-C resistance, and chromosome stability is restored with correction of a 
BRCA1 mutation. Cancer Research 61, 4842-4850. 
Muller CR and Roskelley CD. (2003). Regulation of BRCA1 expression an its 
relationship to sporadic breast cancer. Breast Cancer Research 5(1), 45-52. 
Narod S.A and Foulkes W.D. (2004). BRCA1 and BRCA2: 1994 and beyond. 
Nature Review Cancer 4, 665-676. 
Paull TT, Rogakou EP, Yamazaki, V, Kirchgessner CU, Gellert M and Bonner WM. 
(2000). A critical role for histone H2AX in recruitment of repair factors to nuclear 
foci after DNA damage. Current Biology 10, 886-895. 
Peng G, Lin CJ, Mo W, Dai H, Park YY, Kim SM,  Peng Y, Mo Q, Siwko S, Hu R, 
Lee JS, Hennessy B, Hanash S, Mills G.B, and Lin SY. (2014). Genome-wide 
transcriptiome profiling of homologous recombination DNA repair.  Nature 
Communication 5,3361,1-11. 
Peng G, Yim EK, Dai H, Jackson A, Burgt I, Pan MR, Hu R, Li K, and Lin SY. 
(2009). BRTI1/MCPH1 links chromatin remodeling to DNA damage response. 
Nature Cell Biology 11,865-872. 
 
 
- 108 - 
 
Pierce A, Johnson R, Thompson L, Jasin M. (1999). XRCC3 promotes homology-
directed repair of DNA damage in mammalian cells. Genes & Development 
13,2622-2638. 
Powell S.N and Kachnic L.A. (2003). Roles of BRCA1 and BRCA2 in homologous 
recombination, DNA replication fidelity and the cellular response to ionizing 
radiation. Oncogene 22, 5784-5791. 
Ruffner H and Verama I.M. (1997). BRCA1 is a cell cycle-regulated nuclear 
phosphoprotein. Proc. Natl. Acad. Sci. USA 94, 7138-7143. 
Solimini N.L, Xu Q, Mermel C.H, Liang A.C, Schlabach M.R, Luo J, Burrows A.E, 
Anselmo A.N, Bredemeyer A.L, Li M.Z, Beroukhim R, Meyerson M and Elledge 
S.J. (2012). Recurrent Hemizygous deletions in cancers may optimize proliferative 
potential. Science 6, 104-109. 
Somasundaram K, Zhang H, Zeng YX, Houvras Y, Peng Y, Zhang H, Wu G.S, 
Licht J.D, Weber B.L, and El-Delry W.S. (1997). Arrest of the cell cycle by the 
tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiPl. Nature 389, 
187-190. 
Sung P, Klein H. (2006).  Mechanism of homologous recombination: mediator and 
helicases take on regulatory functions.  Nature Review Molecular Cell Biology 
7,739-750. 
Tibbetts R.S, Cortez D, Brumbaugh K.M, Schully R, Livingston D, Elledge S.J, and 
Abraham R.T. (2000). Functional interactions between BRCA1 and the checkpoint 
kinase ATR during genotoxic stress. Genes & Development 14, 2989-3002. 
 
 
- 109 - 
 
Ueda K, Kawashima H, Ohtani S, Deng WG, Ravoori M, Bankson J, Gao B, Girard 
L, Minna J.D, Roth J.A, Kundra V, and Ji L. (2006). The 3p21.3 Tumor suppressor 
NPRL2 plays an important role in Cisplatin-induced resistance in Human Non–
Small-Cell Lung cancer  cells. Cancer Research 66, 9682-9690. 
Ulrich H.D and Walden Helen. (2010). Ubiquitin signaling in DNA replication and 
repair. Nature Reviews  Molecular Cell Biology, 11, 479-489. 
Vogelstein B, Papadopolous N, Velculescu V.E, Zhou S, Diaz L.A, Kinzler K.W. 
(2013). Cancer genome landscapes. Science 339, 1546-1558. 
Wang B and Elledge SJ. (2007). Ubc13/Rnf8 ubiquitin ligases control foci formation 
of the Rap80/Abraxas/Brca1/Brcc36 complex in response to DNA damage. Proc. 
Natl. Acad. Sci. USA 104 (52), 20759-20763. 
Wang C, Horiuchi A, Imai T, Ohira S, Itoh K, Nikaido T, Katsuyama Y, and Konishi 
Ikuo. (2004). Expression of BRCA1 protein in benign, borderline, and malignant  
epithelial ovarian neoplasms and its relationship to methylation and allelic loss of 
the BRCA1gene. Journal of Pathology 202, 215-223. 
Wu W, Sato K, Koike A, Nishikawa H, Koizumi H, Venkitaraman A.R, and Ohta 
Tomohiko. (2010)  HERC2 is an E3 ligase that targets BRCA1 for degradation. 
Cancer Research 70, 6384-6392. 
Xia Y, Pao G.M, Chen HW, Verma I.M, and Hunter T. (2003). Enhancement of 
BRCA1 E3 ubiquitin ligase activity through direct interaction with BARD1 protein. 
The Journal of Biological Chemistry 278, 5255-5263. 
 
 
- 110 - 
 
Xu B, Kim ST, and Kastan M.B. (2001). Involvement of BRCA1 in s-phase and G2-
phase checkpoints after Ionizing irradiation. Molecular and Cellular Biology 21, 
3445-3450. 
Xu B, O'Donnell A.H, Kim ST, and Kastan M.B. (2002). Phosphorylation of Serine 
1387 in BRCA1 is specifically required for the ATM-mediated S-Phase checkpoint  
after Ionizing Irradiation. Cancer Research 62, 4588-4591. 
Xue W, Kitzing T, Roessler S, Zuber J, Krasnitz A, Schultz N, Revill K, 
WEissmueller S, Rappaport A.R, Simon J, Zhang J, Luo W, Hicks J, Zender L, 
Wang X.W, Powers S, Wigler M, and Lowe S.W. (2012). A cluster of cooperating 
tumor-suppressor gene candidates in chromosomal deletions. Proc. Natl. Acad. 
Sci. USA 109, 8212-8217. 
Yarden R.I, Pardo-Reoyo S, Sgagias M, Cowan K.H, and Broday L.C. (2002). 
BRCA1 regulates the G2/M checkpoint by activating CHK1 kinase upon DNA 
damage. Nature Genetics 30, 285-289. 
Zhan Q, Jin S, Ng B, Plisket J, Shangary S, Rathi A, Brown KD and Baskaran R. 
(2002). Caspase-3 mediated cleavage of BRCA1 during UV-induced apoptosis. 
Oncogene 21, 5335-5345. 
Zhou B.S and Elledge S.J. (2000). The DNA damage response: putting 
checkpoints in perspective. Nature 408, 433-439. 
Zou L and Elledge S.J. (2003). Sensing DNA damage through ATRIP recognition 
of RPA-ssDNA complexes.  Science 300, 1542-1548. 
 
 
 
 
- 111 - 
 
VITA 
Yang Peng was born in Suining, China on November 6, 1982 the son of Huiyao 
Peng and Huiping Xiong. After graduating from Daying High School in Daying , 
China in 2000, he attended Wuhan University in Wuhan, China. And he finished his 
undergraduate studies in 2004 and obtained Bachelor of Science in Biotechnology. 
He then joined Dr. Manuel Varela's lab at Easter New Mexico University in 2005 
and obtained his Master of Science degree in 2008. In the fall semester of 2008, he 
entered the Ph.D. graduate program at the University of Texas Health Science 
Center at Houston, Graduate School of Biomedical Sciences. He then joined Dr. 
Shiaw-Yih Lin's lab at the University of Texas MD Anderson Cancer Center in 
2011, he studied the mechanisms of DNA damage response in breast cancer. 
